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SUMMARY 
This thesis examines factors influencing contemporary outcomes of patients 
managed by the South East Wales upper GI cancer network multidisciplinary 
team. The hypotheses tested were: PET/CT defined tumour characteristics 
influence outcomes of patients with oesophagogastric cancer; Centralisation of 
oesophagogastric cancer services improves outcomes significantly; HER2 
overexpression is a poor prognostic indicator following oesophagogastric cancer 
resection; An involved circumferential resection margin (CRM) following 
oesophagectomy is an independent predictor of survival.   
PET/CT N stage was an independent and significant predictor of survival 
(p=0.022). SUVmax correlated positively and significantly with endoluminal 
ultrasound-defined tumour volume (Spearman’s rho=0.339, p=0.001). 
Centralisation increased the proportion of patients receiving potentially curative 
treatment by 78% (p<0.0001), reduced serious operative morbidity by 50% 
(p=0.062), shortened total length of hospital stay from 16 days to 13 days 
(p=0.024) and improved median and 1-year survival from 8.7 months and 39% to 
10.8 months and 46.8% respectively (p=0.032). Centralisation was an 
independent and significant predictor of survival (p=0.03). HER2 overexpression 
and gene amplification was a predictor of poor prognosis in patients with curable 
oesophageal cancer (p=0.03). CRM involvement was also an indicator of poor 
prognosis in these patients (p<0.001). The College of American Pathologists’ 
criteria differentiate a higher risk group than Royal College of Pathologists’ 
criteria but overlook a patient group with similar poor outcomes (p<0.001).  
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1.1 EPIDEMIOLOGY 
Gastric and oesophageal cancer are the fourth and eighth most common cancer 
and second and fourth most common cause of cancer-related death worldwide 
respectively (Ferlay et al. 2010). Annually, this accounts for 990,00 and 462,000 
people diagnosed worldwide with gastric and oesophageal cancer resulting in 
740,000 and 386,000 deaths respectively (Ferlay et al. 2010; Jemal et al. 2011). 
As large geographical variation exists, these two cancer sites represent the 
thirteenth and eleventh most common cause of cancer and the sixth and fifth 
most common cause of cancer-related death in the United Kingdom respectively 
(Cancer Research UK 2012).  
Worldwide, the incidence of gastric cancer has been declining for several 
decades (Parkin 2006). Although the cause is not fully understood, this decline 
has been attributed to improvements in diet, food preservation and a decrease in 
prevalence of Helicobacter pylori infection (Cancer Research UK 2012). On the 
other hand, the incidence of the two main histological types of oesophageal 
cancer namely squamous cell carcinoma (SCC) and adenocarcinoma (ACA) has 
changed significantly over the last three decades.  SCC accounts for most of the 
oesophageal cancer in developing countries and the incidence has declined in 
Western countries (Vizcaino et al. 2002). Conversely, the incidence of ACA has 
been increasing significantly in most Western countries, with the UK reporting the 
highest ACA incidence in the world (Bollschweiler et al. 2001).  
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1.2 AETIOLOGY 
1.2.1 Gastric cancer 
Gastric cancer is the result of a long multi-step process involving interactions 
between environmental factors which stimulate changes, H. Pylori infection and 
host genetic susceptibility. It is a disease of lower socio-economic groups; 
tobacco smoking is more prevalent in these groups and smokers are at a 1.6 fold 
risk of developing gastric cancer compared to non-smokers (Lindblad et al. 
2005). Certain occupations more common in these groups such as coal mining 
and pottery have also been found to be associated with an increased risk of 
developing gastric cancer (Allum 2009). However, lifestyle factors in particular 
dietary habits are confounding factors in proving a direct causal relationship for 
these occupations. Diets which consists of a high proportion of salted or pickled 
foods, dried fish and meat and refined carbohydrates significantly increase the 
risk of developing gastric cancer (Compare et al. 2010). Conversely, foods rich in 
antioxidants such as fresh fruit and vegetable have been shown to decrease this 
risk (Gonzalez et al. 2010).   
Besides diet, H. Pylori infection has been implicated in gastric carcinogenesis 
and since 1994, the International Agency for Research on Cancer designated H. 
Pylori as a type 1 carcinogen (IARC 1994). It is postulated that H. Pylori infection 
induces an environment which is susceptible to malignant transformation by 
reducing gastric juice ascorbic acid thus inducing tissue monocytes to produce 
reactive oxygen intermediates which are potent carcinogens (Sobala et al. 1993).  
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1.2.2 Oesophageal cancer - Squamous cell carcinoma  
In the West, smoking and alcohol are the main risk factors in the development of 
oesophageal SCC (Ashktorab et al. 2011). Both these factors are synergistic and 
exhibit a positive dose-response – heavy smokers and drinkers have up to 2-3 
fold greater risk compared to regular users (Szymanska et al. 2011). Additional 
risk factors such as hookah smoking, nass use, opium consumption and hot tea 
drinking have been implicated in the East (Mao et al. 2011). Diets which lack 
important nutrients such as riboflavin, vitamin A and C also predispose to the 
development of oesophageal SCC (Hu et al. 1994).  
Various other factors have also been reported to increase the risk of SCC of the 
oesophagus. Corrosive injury resulting in oesophageal strictures have been 
reported to increase the risk of oesophageal SCC by 1000 fold (Ti 1983). Patients 
with long standing achalasia, a motility disorder of unknown aetiology which 
results in stasis and fermentation of food residue causing oesophagitis have a 
140 fold increased risk of malignant transformation (Leeuwenburgh et al. 2006). 
However, the treatment of achalasia does not appear to reduce this risk. The 
combination of dysplasia, iron-deficiency anaemia, koilonychias and 
oropharyngeal mucosal atrophy otherwise known as Plummer-Vinson syndrome 
and tylosis which is a rare autosomal dominant disorder are associated with 
oesophageal SCC (Ribeiro et al. 1996).  
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1.2.3 Oesophageal cancer - Adenocarcinoma  
The rising incidence of ACA of the oesophagus in western countries appear to 
parallel the increase in prevalence of gastro-oesophageal reflux disease (GORD) 
and the obesity epidemic (Bollschweiler et al. 2001). GORD, which affects up to 
10% of adults on a daily basis (Cameron 1997) has been shown to increase the 
odds of developing oesophageal ACA by 2 to 5 fold in a case-controlled study 
(Chow et al. 1995). Moreover, the risk of malignancy is related to the severity of 
GORD. Patients with recurrent and prolonged symptoms have increased odds of 
developing ACA by up to 8 fold compared with patients who have minimal 
symptoms (Lagergren et al. 1999). This increased risk is related to the 
replacement of the normal squamous cell lining of the distal oesophagus with 
columnar-lined epithelium (Barrett’s metaplasia) which is detected in 12% of 
patients undergoing endoscopy for GORD (Winters et al. 1987). The 
development of ACA in a Barrett’s segment follows a progressive sequence from 
intestinal metaplasia to low grade dysplasia (LGD), high grade dysplasia (HGD) 
and finally to cancer (Jankowski et al. 1999). This is thought to be an adaptive 
response of the oesophageal squamous epithelium to the chronic inflammation 
caused by prolonged exposure to acid reflux. Although the natural history of 
Barrett’s metaplasia is not fully understood, up to 23% of patients with Barrett’s 
oesophagus develop LGD and the risk of progression from LGD to HGD or 
cancer is between 10% to 28% (Miros et al. 1991). 
Obesity mechanically predisposes to GORD and has been shown to increase the 
risk of the development of ACA by 3 to 6 fold (Cheng et al. 2000). However, 
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studies have shown that this increased risk is independent of GORD (Lindblad et 
al. 2005) and is more pronounced in women (Reeves et al. 2007). 
1.3 DIAGNOSIS 
1.3.1 Symptoms 
The principle symptoms of patients with oesophagogastric cancer are dyspepsia 
and dysphagia. According to the British Society of Gastroenterology guidelines, 
alarm symptoms which indicate advanced disease and mandate urgent 
endoscopy include persistent dyspepsia in patients over the age of 55, 
dysphagia, anorexia, vomiting, weight loss and anaemia (BSG 2004). However, 
the presence of alarm symptoms decreases the chance of potentially curative 
surgery and long-term survival (Stephens et al. 2005). A low threshold for 
investigation should therefore be adopted to detect early tumours especially in 
high-risk individuals. 
1.3.2 Screening  
Screening programmes for oesophagogastric cancer have been implemented in 
high-prevalence populations with well documented benefits. Oesophageal cancer 
screening in parts of China with the highest incidence involves collecting 
oesophageal mucosal cells by withdrawing a swallowed balloon covered with a 
fine mesh (Shu 1983). Patients with abnormalities are then subjected to 
endoscopy without the need for radiology. 
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On the other hand, the screening of gastric cancer in Japan is based on double-
contrast radiology followed by endoscopic assessment of any abnormal findings 
(Hisamichi 1989). The programme which was introduced in the 1960s for men 
aged over 40 years has led to earlier diagnosis and an improved 5-year survival 
of up to 30% (Tsubono et al. 2000). 
There are currently no screening programmes in the UK where the prevalence of 
oesophagogastric cancer is lower than the East. Surveillance endoscopy is 
offered to high-risk groups of patients with gastric ulcers and Barrett’s 
oesophagus (BSG 2004). 
1.3.3 Endoscopy 
Upper GI endoscopy is the preferred investigation for the diagnosis of 
oesophagogastric cancer as it allows biopsy for histological confirmation. 
Radiological diagnosis in the form of a barium swallow is reserved for patients 
who are unable to tolerate endoscopy as biopsies are not obtainable.  
1.4 STAGE CLASSIFICATIONS  
1.4.1  Tumour Node Metastases classification 
Prior to 1986, numerous staging classification systems were in use. Following 
agreement between the American Joint Committee on Cancer, Japanese Joint 
Committee and International Union Against Cancer, a single Tumour Node 
Metastases (TNM) staging classification was introduced and it is now in its 7th 
edition (Sobin et al. 2009). This unified classification facilitates planning of 
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treatment, determining prognosis and allows comparison of outcomes between 
centres. The TNM system is based on three factors; T stage (depth of invasion of 
primary tumour), N stage (number of regional lymph node metastases) and M 
stage (presence or absence of distant metastases). 
1.4.2 T Stage 
The T stage is based on the depth of tumour invasion and is similar for gastric 
(Table1.1) and oesophageal cancers (Table 1.2). Early tumours are those which 
are confined to the mucosa and submucosa and confer a significantly better 
prognosis compared to more advanced tumours. There is strong evidence that T 
stage is an important prognostic indicator in oesophagogastric cancer (Ide et al. 
1994; Paraf et al. 1995; Lozac'h et al. 1997). 
1.4.3 N Stage 
The N stage or number of regional lymph node metastases is the most important 
prognostic factor in both gastric and oesophageal cancer and is used to 
determine the most appropriate treatment using multi-modal therapy (Mariette et 
al. 2003; Kunisaki et al. 2005). The accuracy of the N stage is dependent on the 
number of lymph nodes harvested and a minimum of count of 10 and 15 should 
be examined to designate the stage as N0 in oesophageal (Twine et al. 2009) 
and gastric cancer (Bouvier et al. 2002) respectively. This also facilitates the 
calculation of the lymph node ratio (LNR = number of metastatic nodes divided by 
the lymph node count) which has been shown to be an important prognostic 
factor (Dhar et al. 2007; Lagarde et al. 2007). 
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1.4.4 M Stage 
The M stage is the assessment of distant metastases. In gastric cancer, the M 
stage is simply divided into M0 and M1 which represents the absence and 
presence of distant metastases respectively. This classification has now been 
adopted in oesophageal cancer and metastases in coeliac lymph nodes is no 
longer classified as M1a (Sobin et al. 2009). 
Table 1.1 TNM 7 for gastric cancer 
T stage     N Stage    
 T1a Lamina propria  N0 None  
 T1b Submucosa   N1 1-2 nodes 
 T2 Muscularis propria  N2 3-6 nodes 
 T3 Subserosa   N3a 7-15 nodes 
 T4a Perforates serosa  N3b ≥ 16 nodes 
 T4b Adjacent structures 
 
Table 1.2 TNM 7 for oesophageal cancer 
T stage     N Stage    
 Tis Carcinoma in-situ  N0 None 
T1a Lamina propria  N1 1-2 nodes  
 T1b Submucosa   N2 3-6 nodes 
 T2 Muscularis propria  N3 >6 nodes 
 T3 Adventitia    
 T4a Pleura, pericardium,  
  Diaphragm, peritoneum 
 T4b Aorta, trachea, vertebrae 
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1.5 PREOPERATIVE STAGING 
Accurate preoperative radiological and endoscopic staging is vital in ensuring the 
most appropriate stage-directed treatment is offered to patients. As up to 50% of 
patients present with disseminated disease, the initial investigation is aimed at 
determining the M stage. In the absence of metastatic disease, further 
investigations to define the local T and N stages are indicated to tailor 
management appropriately. The principal imaging modalities are computed 
tomography (CT), positron emission tomography combined with CT (PET/CT), 
endoscopic ultrasonography (EUS) and diagnostic laparoscopy.  
1.5.1  Computed Tomography  
CT of the chest, abdomen and pelvis with intravenous contrast is the initial 
radiological modality used as it allows the assessment of the primary tumour and 
more importantly, the detection of distant metastases. Over the last decade, 
significant improvements in CT with the use of multiple detectors have resulted in 
improved diagnostic accuracy which is further enhanced by specialist radiologists 
(Barry et al. 2002). 
The accuracy of T stage as defined by CT is dependent on adequate distension 
by water with the addition of anti-peristaltic agents prior to imaging. Tumours 
around the oesophagogastric junction are dependent on gravity and can 
therefore be imaged in the prone or decubitus position for improved accuracy 
(Allum et al. 2011). The ability to detect invasion of surrounding structures as 
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determined by the loss of the fat plane around the oesophagus and stomach can 
be improved further by using multiplanar reformat images (Bhandari et al. 2004). 
The sensitivity and specificity of N stage defined by CT are 50% and 83% 
respectively (van Vliet et al. 2008). Differentiation between lymph node 
metastases and benign enlargement is difficult on CT and size criteria for 
malignant involvement is controversial and a combination with positron emission 
tomography (PET) significantly improves the accuracy (Gillies et al. 2012). 
The main strength of CT is the detection of distant metastases with a sensitivity 
and specificity of 52% and 91% respectively (van Vliet et al. 2008). However, 
small volume metastatic disease can be missed by CT and investigations such as 
laparoscopy and PET/CT can improve the accuracy of M stage.   
1.5.2 Positron Emission Tomography  
Positron emission tomography (PET) is a nuclear medicine technique which 
relies on the production of gamma rays following introduction of a radionuclide 
intravenously. 2-[(18F)] fluoro-2-deoxy-d-glucose (FDG) is the most commonly 
used radionuclide which remains intracellular until radioactive decay occurs. The 
rate of cellular tracer uptake is proportional to metabolic activity and malignant 
tumours usually have higher metabolic rates compared with normal tissue 
(Branstetter et al. 2005).  
The first commercial PET scanner was manufactured by Siemens and used in 
UCLA, Los Angeles in 1976. Since then, integrated PET/CT has been developed 
which provides both functional and anatomical data (Beyer et al. 2000). This 
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combination allows co-registration of the PET and CT data as patient position is 
unchanged therefore minimising movement artefacts. PET/CT is now used in the 
staging and assessment of treatment response of various cancers such as 
breast, lung, lymphoma, thyroid and gastrointestinal (Endo et al. 2006). 
The main role of PET/CT in oesophagogastric cancer is the detection of distant 
nodal and metastatic disease. The sensitivity and specificity for the identification 
of distant metastases by PET/CT is 67% and 97% respectively (Ott et al. 2006). 
Moreover, the addition of PET/CT in the staging algorithm of oesophageal cancer 
allows the detection of distant metastases in 10% of patients not detected by CT 
and altered management in up to 26% (Noble et al. 2009; Gillies et al. 2011). The 
prognostic role of PET/CT defined tumour characteristics is explored in the 
following chapter. 
Another potential role of PET/CT is in the assessment of response to 
neoadjuvant chemo/radiotherapy prior to surgery. PET/CT can measure changes 
in metabolic activity and can therefore identify residual disease. However, recent 
studies have not been conclusive and further research is needed prior to its 
routine use in assessment of response (Muijs et al. 2010; Klayton et al. 2012). 
1.5.3 Endoscopic Ultrasonography  
Endoscopic ultrasonography (EUS) is an established modality in the locoregional 
staging of oesophageal and junctional tumours and is indicated following 
exclusion of metastatic disease by CT or PET/CT. The overall accuracy for T 
stage is 67-78% and EUS is highly effective at discriminating between T1/2 from 
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T3/4 disease (Kelly et al. 2001). This helps selecting patients for neoadjuvant 
therapies which are used to downstage tumours prior to surgery.  The accuracy 
of N stage is 65-75% and further information can be obtained by performing FNA 
of suspicious lymph nodes which can improve N staging accuracy to over 90% 
(Chang et al. 2003).  
The main drawback of EUS is the failure to cross a stricture which occurs in up to 
25% of patients (Vickers et al. 1998).  However, valuable staging information can 
still be obtained using blind probes and aid decision-making (Vickers et al. 1998).  
In addition to these diagnostic roles, EUS defined tumour characteristics such as 
tumour length (Twine et al. 2010), total length of disease (Davies et al. 2012) and 
tumour volume (Twine et al. 2010) provide important prognostic information. 
1.5.4 Staging Laparoscopy 
Laparoscopy allows the detection of peritoneal disease not detected by CT. 
Moreover the assessment of serosal involvement and invasion of adjacent 
tissues can be determined. Laparoscopy is used routinely in patients with distal 
oesophageal or junctional tumours (Allum et al. 2011) as it prevents unnecessary 
laparotomy in up to 18% of patients (de Graaf et al. 2007).  
1.6 SURGICAL TREATMENT 
1.6.1 Gastrectomy 
The extent of resection is determined by the position and preoperative stage of 
the cancer. In patients with early gastric cancer, proximal or distal subtotal 
resection with limited D1 lymphadenectomy (Allum et al. 2011) is indicated. A 
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total gastrectomy or oesophagogastrectomy can be performed for tumours 
around the cardia. 
The extent of lymphadenectomy has been a topic of debate among Western 
surgeons in the last two decades. In D1 lymphadenectomy, only the perigastric 
nodes closest to the primary tumour are removed en bloc with the stomach. 
Systematic D2 lymphadenectomy involves the removal of the perigastric nodes 
and distant nodes along the main arteries supplying the stomach (first 2 tiers of 
lymph nodes, N1 and N2). In contrast to many Western surgeons, the Japanese 
have long advocated the more radical D2 approach, reserving D1 surgery for 
elderly patients with early disease and associated co-morbidities. Initial results 
from two Western randomised controlled trials have shown little difference 
between D1 and D2 lymphadenectomy (Cuschieri et al. 1996; Bonenkamp et al. 
1999; Cuschieri et al. 1999). However, long-term results in the Dutch trial has 
shown improved survival following D2 lymphadenectomy (Songun et al. 2010) 
which is now the recommended standard approach (Allum et al. 2011). At 
present, there is no role for extended lymphadenectomy beyond the second tier 
nodes as two multicentre trials in Japan comparing D2 and D4 lymphadenectomy 
concluded that D4 did not result in improved survival but increased morbidity 
(Sasako et al. 2008; Yonemura et al. 2008).  
Studies have shown that minimally invasive resection for gastric cancer including 
D2 lymphadenectomy can be performed safely (Huscher et al. 2005; Tanimura et 
al. 2007). However, most studies include patients with early (T1 and T2) cancers 
and a meta-analysis of open versus laparoscopic-assisted distal gastrectomy 
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(LADG) revealed a trend towards faster postoperative recovery at the expense of 
longer operating times and a reduced nodal yield in LADG (Memon et al. 2008). 
1.6.2 Oesophagectomy 
The two main operative approaches for oesophagectomies are the transthoracic 
(Ivor-Lewis) and the transhiatal route which depends on tumour location, extent 
of lymphadenectomy, patient factors and experience of the surgeon. The 
transthoracic approach is a two stage procedure involving the resection of the 
thoracic oesophagus and a complete posterior mediastinal lymphadenectomy via 
an upper midline laparotomy and a right postero-lateral thoracotomy. The 
transhiatal procedure is performed via an abdominal roof-top and a left cervical 
incision. The initial gastric and oesophageal mobilisation is performed under 
direct vision until the inferior pulmonary vein followed by blunt dissection of the 
remaining oesophagus. Reconstruction is performed using a gastric conduit with 
a left cervical anastomosis. 
The advantages of the transhiatal approach are the significantly lower 
postoperative morbidity rates and quicker recovery compared to the transthoracic 
approach (Hulscher et al. 2002; de Boer et al. 2004). This is at the expense of 
inadequate mediastinal lymphadenectomy which can be achieved with the 
transthoracic approach. However, overall survival difference is minimal and the 
transhiatal route is usually reserved for patients with early stage node negative 
tumours who may not tolerate a thoracotomy because of comorbidities (Allum et 
al. 2011).  
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The development of minimally invasive technique is still in its infancy and early 
experiences from cohort studies have shown that short-term outcomes are 
acceptable with adequate lymph node yield (Palanivelu et al. 2006; Berrisford et 
al. 2008). Data from well-designed randomised controlled trials are needed prior 
to routine use of these new techniques. 
 
1.7 ENHANCED RECOVERY AFTER SURGERY 
Traditional perioperative care of patients undergoing major gastrointestinal 
resections dictated the need for prolonged periods of fasting and gastrointestinal 
tract rest until the return of normal function. This has lead to patients routinely 
staying in hospital for over 15 to 20 days even in the absence of major 
complications (Karl et al. 2000; Hofstetter et al. 2002). Over the last decade, 
enhanced recovery after surgery (ERAS) programmes have been implemented 
routinely in colorectal surgical practice. Originally described by Kehlet in 
Copenhagen, the ERAS programme is a multidisciplinary package of measures 
for patients undergoing colorectal surgery which includes preoperative patient 
education, carbohydrate loading, goal directed anaesthesia, early postoperative 
enteral nutrition and mobilisation (Basse et al. 2000). This has resulted in 
improved postoperative morbidity and length of hospital stay (Varadhan et al. 
2010). However, ERAS in upper gastrointestinal surgery is less well developed 
with only the publication of a few small trials and observational studies (Wang et 
al. 2010; Tang et al. 2013).  
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1.8 NEOADJUVANT THERAPY 
Multimodal therapy has been shown to be beneficial in patients with 
oesophagogastric cancer. Surgery alone is reserved for the minority of patients 
who present with early disease due to the high recurrence rates in advanced 
tumours. Neoadjuvant therapy has the potential advantages of improving 
resectability and swallowing and treating micrometastases prior to surgery. The 
two largest randomised controlled trials of preoperative chemotherapy versus 
surgery alone have reported conflicting results. The American Intergroup Trial 
(INT 0113) of 440 patients did not report any significant differences in survival in 
the two arms (Kelsen et al. 1998). However, the largest and most influential trial 
from the UK of over 800 patients showed a significant survival advantage for 
patients receiving preoperative chemotherapy (5 year survival of 23% vs. 17%) 
(MRC Oesophageal Cancer Working Group 2002). This is therefore the standard 
of care in the UK. The recently completed MRC OEO5 trial comparing OEO2 
chemotherapy with four cycles of ECX (epirubicin-cisplatin-capecitabine) may 
alter practice if this regimen is found to further improve survival (Allum et al. 
2009). 
Preoperative chemoradiotherapy (CRT) is used in patients with rectal cancer who 
have a threatened CRM. However, its use in oesophageal cancer is 
controversial. The only randomised trial comparing preoperative chemotherapy 
with preoperative CRT of 126 patients showed a non-significant improvement in 3 
year survival in the preoperative CRT group (Stahl et al. 2009). Currently, 
preoperative CRT is only used in the context of a clinical trial in the UK. 
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1.9 NONSURGICAL TREATMENT 
1.9.1 Endoscopic techniques 
Endoscopic techniques such as endoscopic mucosal resection (EMR), 
submucosal dissection (ESD), radiofrequency ablation (RFA), photodynamic 
therapy (PDT) and argon plasma coagulation (APC) have developed significantly 
over the last decade. As these techniques do not treat regional lymph nodes, the 
indications are limited to patients with early cancer (high grade dysplasia and 
T1a) and to ablate high-risk mucosa. The risk of lymph node metastasis is related 
to the depth of invasion of the tumour and histological type. There is a suggestion 
that squamous cell carcinoma is more aggressive than adenocarcinoma (Eguchi 
et al. 2006). The risk of nodal metastasis in patients with adenocarcinoma and 
squamous cell carcinoma confined to the mucosa (T1a) is 0% and up to 18% 
respectively (Eguchi et al. 2006; Griffin et al. 2011).  Once the tumour invades the 
submucosa (T1b), the risk of lymph node metastasis rises significantly up to 60% 
(Gockel et al. 2011). These patients should therefore undergo oesophagectomy 
as the most definitive treatment aimed at cure.   
After removing high-risk lesions with EMR or ESD, the high-risk mucosa will need 
to be ablated, most frequently with RFA, but other options include PDT and APC. 
These techniques have the potential for complete eradication of high grade 
dysplasia and Barrett’s dysplasia in over 90% but recurrence is reported in up to 
10% (Ragunath et al. 2005; Ganz et al. 2008). Patients undergoing these 
therapies usually require repeat treatment and should be performed in specialist 
centres (Allum et al. 2011). 
22 
 
1.9.2 Definitive chemoradiotherapy 
The high proportion of elderly patients diagnosed with oesophageal cancer who 
have significant comorbidity unfit for major surgery has fuelled the search for non-
surgical curative options. High response rates and pathological complete 
response (pCR) rates after chemoradiotherapy (CRT) has lead to the adoption of 
this modality as a definitive treatment strategy (Gwynne et al. 2013). Certainly in 
upper squamous cancers, dCRT can achieve local control in up to 70% of 
patients and surgery is only reserved as a salvage option (Denham et al. 2003). 
Despite the lack of randomised trials comparing dCRT versus surgery for 
adenocarcinoma, numerous studies have reported long-term survival following 
dCRT comparable to surgical series (Chan et al. 1999; Bedenne et al. 2007; 
Morgan et al. 2009; Gwynne et al. 2011). At present, dCRT is reserved for 
patients deemed unsuitable for surgery although its role in patients with operable 
adenocarcinoma warrants further investigation. 
 
1.10 BIOMARKERS  
Cancer biomarkers are biological molecules found in blood or other tissues that 
can be used not only to identify the presence of a tumour, but also to determine 
its stage, subtype and ability to respond to therapy (Chhatrala et al. 2014). These 
assays are useful for cancer detection, diagnosis, patient prognosis and 
treatment selection. The poor survival rates from oesophagogastric cancer has 
led to the search for targeted therapies with antagonists of growth factor signaling 
transduction pathways (Ekman et al. 2007). These growth factors are polypeptide 
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molecules that regulate various cellular responses including cell proliferation by 
binding to specific receptors on the cell surface which activates tyrosine kinase 
pathways (Heldin 1995). If deregulated, these pathways can promote 
tumorigenesis.  
 
1.10.1 Human Epidermal Growth Factor Receptors 
The human epidermal growth factor receptor (HER) family of growth factors 
comprise of four members: EGFR (HER1, ErbB-1), HER2 (ErbB-2, Neu), HER3 
(ErbB-3) and HER4 (ErbB-4) (Bazley et al. 2005). These receptors are tyrosine 
kinases that are activated by ligand-induced dimerization. However, HER2 does 
not have a ligand but is used as a heterodimeric partner by the other receptors 
(Bazley et al. 2005). HER family members are commonly activated in various 
cancers by mutations or overexpression leading to signals that promote 
proliferation, survival, migration and angiogenesis (Ekman et al. 2007). 
 
1.10.2 Human Epidermal Growth Factor Receptor 2  
Amplification of the HER2 gene and overexpression of HER2 in gastric cancer 
was first described in 1986 (Yamamoto et al. 1986) and since then, numerous 
studies have confirmed these findings (Jorgensen et al. 2012). Since 2010 
following the ToGA trial, trastuzumab, an anti-HER2 agent in combination with 
chemotherapy was approved for the treatment of patients with HER2 positive 
advanced inoperable gastric and junctional cancer (Bang et al. 2010). However, 
there is still a lack of evidence of its use in oesophageal cancer.  
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1.10.3 Prognostic significance of HER2  
Gastric cancer 
A recent systematic review of 49 studies totaling 11337 patients with gastric 
cancer, most of whom had undergone curative gastrectomy found that HER2 
overexpression occurred in 18% (4-53%) and was associated with a poorer 
survival (Chua et al. 2012).  
 
Table 1.3  Association of HER2 status and survival in patients with gastric cancer 
(Chua et al. 2012) 
 HER2 positive HER2 negative 
3 year disease free survival, %  58   86  
5 year overall survival, %   42   52 
Median survival (range), months  21 (10 – 57)  33 (13 – 80) 
 
Oesophageal cancer 
The frequency of HER2 amplification ranges from 15 to 19% in patients with 
oesophageal adenocarcinoma (Brien et al. 2000; Reichelt et al. 2007; Hu et al. 
2011). There are reports indicating that HER2 expression may change during 
tumour progression. HER2 expression has been reported to be lost during 
development of oesophageal adenocarcinoma (Sauter et al. 1993) or a late event 
(Walch et al. 2004). Moreover, the association between HER2 overexpression 
and survival in patients with oesophageal cancer is unclear and reports have 
been conflicting (Hu et al. 2011).  
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1.11 SERVICE RECONFIGURATION 
Centralisation of complex cancer surgery into high-volume centres is a subject of 
debate in many countries. Improvements in care can be achieved by collating 
multidisciplinary expertise and experience with specialised equipment in centres 
of excellence (Brusselaers et al. 2014). However, these benefits will need to be 
offset against potential disadvantages such as long travel distances, social 
isolation (Bilimoria et al. 2008) and the negative impact on waiting times for the 
benign operative workload in specialist units (Forshaw et al. 2006). Nevertheless, 
the Association of Upper Gastrointestinal Surgeons has recommended that these 
units should consist of four to six surgeons, each performing a minimum of 15 to 
20 resections per year and serving a population of 1 to 2 million (AUGIS 2011). 
Compliance with this guidance has been achieved in England but received lesser 
support in Wales. Indeed, the most recent audit of activity related to 
oesophagogastric management demonstrated that many surgeons’ case loads 
remained small, staging strategies were idiosyncratic, operative mortality was 
12%, and 2 year survival was 42% (Pye et al. 2001) following curative surgery 
compared with 6% and 75% in England (Sue-Ling et al. 1993).  
Numerous population based studies have reported improved short-term 
outcomes (van Lanschot et al. 2001; Wouters et al. 2012) and long-term survival 
(van de Poll-Franse et al. 2011; Brusselaers et al. 2014) in high-volume units. 
However, there are only a handful of reports from individual units in England 
detailing actual improvements following centralisation (Branagan et al. 2004; 
Forshaw et al. 2006; Boddy et al. 2012). In South East Wales, centralisation of 
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upper gastrointestinal cancer services at the University Hospital of Wales 
commenced in August 2010 serving a population of 1.4 million, following a 
protracted period of negotiation between politicians, managers and clinicians.  
 
1.12  AIMS AND HYPOTHESES 
In light of the above, the aims of this thesis are to address the following according 
to the patient journey from pre-operative staging after diagnosis, surgical 
treatment in the era of centralisation of specialist services, through to the 
examination of post-operative histological factors which influence prognosis: 
1. To determine the correlation between 18-FDG PET/CT defined SUVmax 
and EDTV in patients with oesophageal cancer and their relative 
prognostic significance 
2. To determine the impact of centralisation on Upper GI cancer survival at 
one year 
3. To determine the influence of HER2 on outcomes in patients with operable 
oesophageal cancer 
4. To determine the prognostic significance of HER2 receptor expression at 
index biopsy and definitive surgery 
5. To determine the influence of CRM involvement in patients with operable 
oesophageal cancer 
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The hypotheses are: 
1. A significant positive correlation exists between SUVmax and EDTV. 
PET/CT and EUS defined tumour characteristics are important predictors 
of survival in patients with oesophageal cancer. 
2. Centralisation of Upper GI cancer services improves one year survival. 
3. HER2 overexpression is associated with poorer outcomes in patients with 
operable oesophageal cancer.  
4. Endoscopic biopsy is accurate at predicting HER2 status.  
5. CRM involvement is associated with poorer outcomes following 
oesophagectomy.  
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Chapter 2 
 
 
 
Prognostic significance of 18-FDG PET/CT and EUS defined tumour 
characteristics in patients with oesophageal cancer. 
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2.1 SUMMARY 
The aim of this study was to determine the correlation between 18-
fluorodeoxyglucose positron emission tomography/computed tomography 
(PET/CT) defined maximum standardised uptake value (SUVmax) and 
endoluminal ultrasound-defined tumour volume (EDTV) in patients with 
oesophageal cancer (OC) and their relative prognostic significance. 
 
One hundred and eighty-five consecutive patients with OC were staged with CT, 
EUS and PET/CT. The maximum potential EDTV was calculated (πr2L, where r = 
tumour thickness and L=total length of disease including proximal and distal 
lymph node metastases). Primary outcome measure was survival from diagnosis. 
 
Ninety-one percent of patients (168/185) had FDG-avid tumours on PET/CT. 
SUVmax correlated positively and significantly with EDTV (Spearman’s rho = 
0.339, p=0.001). On univariate analysis, survival was inversely related to the 
PET/CT lymph node metastasis count (LNMC, p=0.015), EUS N stage (p=0.002), 
EDTV (<48 cm3, p=0.001), EUS total length of disease (p=0.001), SUVmax 
(p=0.002), PET/CT N stage (p<0.0001), and EUS LNMC (p<0.0001). On 
multivariate analysis two factors were significantly and independently associated 
with survival: EDTV (HR, 3.118; 95% CI, 1.357-7.167; p = 0.007), and PET/CT N 
stage (HR, 0.496; 95% CI, 0.084-1.577; p=0.022). 
 
30 
 
EDTV and PET/CT N stage were important predictors of survival and further 
research is needed to identify critical prognostic values. 
 
2.2 INTRODUCTION   
Contemporary radiological staging of patients diagnosed with oesophageal 
cancer (OC) has recently been upgraded to include 18-fluorodeoxyglucose (FDG) 
positron emission tomography integrated with computed tomography (PET/CT) 
(Allum et al. 2011) into the previous algorithm of CT followed by endoscopic 
ultrasound (EUS). The benefits accrued from this strategy include the detection of 
distant metastases not detected by CT in about 10% of patients, and altered 
management in as many as 26% (Noble et al. 2009; Gillies et al. 2011). 
Moreover, there is growing evidence that the degree of tracer uptake by the 
tumour measured as the maximum standardised uptake value (SUVmax) is an 
important prognostic factor (Rizk et al. 2006; Pan et al. 2009).  
 
EUS is the principal imaging modality for assessing the depth of tumour invasion, 
lymph node metastasis count (ELNMC) and the total length of disease including 
the proximal and distal lymph node metastases (ELoD) (Kelly et al. 2001). ELoD, 
ELNMC and the maximum endoluminal ultrasound-defined tumour volume 
(EDTV), derived from the ELoD have been shown to be significant and 
independent predictors of survival in patients with OC (Twine et al. 2010). 
However, despite the importance of these factors in defining the optimum 
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treatment, ELoD ELNMC and the derived EDTV are not routinely reported in 
standard EUS examinations. 
 
Therefore, the aim of the present study was to determine the correlation between 
FDG PET/CT defined SUVmax and EDTV in patients with OC and their relative 
prognostic significance. 
 
2.3 METHODS    
2.3.1 Patient selection and staging 
All patients diagnosed with oesophageal cancer who underwent PET/CT imaging 
in the South East Wales regional Upper GI cancer network were studied 
prospectively between January 2009 and June 2011. Patients with Siewert type 
III oesophagogastric junctional cancer with proximal extension also underwent 
PET/CT. Patients proceeded to PET/CT imaging only if they were suitable for 
potentially curative treatment on the grounds of CT stage and performance 
status, and was arranged concurrent with EUS. Patients’ fitness was assessed by 
means of cardiopulmonary exercise testing (CPX) (Older et al. 2000) and a final 
management plan was determined at the regional cancer network 
multidisciplinary team (MDT) meeting. All staging investigations were reported in 
accordance with the UICC tumour-nodes-metastasis (TNM) 7th Edition (Sobin et 
al. 2009). The primary outcome measure was survival from diagnosis. Informed 
consent was obtained from all patients. Ethical approval was sought from the 
regional ethics committee, but a formal application was deemed unnecessary. 
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2.3.2 PET/CT protocols 
PET/CT examinations on 185 patients were performed at two centres. At the first 
centre, 87 patients underwent PET/CT examinations performed on a Philips 16 
section Gemini GXL dedicated PET/CT system (Philips Medical Systems, 
Cleveland, OH, USA). The uptake time was 60 minutes. A standard dose of 350 
MBq of FDG was injected. Reconstructions were performed using a three-
dimensional (3D) acquisition with non-time-of-flight acquisition for 4 minutes per 
bed position. 
 
Ninety-eight patients were imaged at the second centre on a GE discovery 690 
PET/CT system with time-of-flight acquisition (GE Medical Systems, Waukesha, 
WI, USA). Patients were injected with 3MBq/kg (minimum 200 MBq). Uptake time 
at the second centre was 90 minutes. Acquisitions were obtained for 3 minutes 
per bed position. Image analysis was performed on a GE Xeleris workstation. At 
both centres, all patients were starved for a minimum of 6 hours prior to imaging. 
The SUVmax was determined for all patients by identifying the most avid part of 
the primary tumour on the maximum intensity projection images and placing a 2 
cm diameter spherical region of interest over this, while avoiding activity not 
arising within the primary tumour. The maximum SUV value within this was 
recorded as the SUVmax. This method was consistent between the two centres. 
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2.3.3 Details of endosonography 
An initial endoscopic examination was performed using a 9 mm diameter 
Olympus P-10 gastroscope (Key Med, Southend, UK) to assess the degree of the 
oesophageal luminal stenosis. Patients with an estimated oesophageal luminal 
diameter less than 15 mm underwent examination using the smaller-diameter 
MH-908 oesophagoprobe (Key Med). Oesophageal dilation (Savary-Gilliard, 
Cook Medical, Bloomington, IN) was performed before endosonography for 
patients with oesophageal lumens less than 9 mm. The type of echoendoscope 
used was at the discretion of the endoscopist. The primary oesophageal tumour 
was assessed, together with an evaluation of the paraoesophageal anatomic 
structures as described previously (Bowrey et al. 1999). The criteria for malignant 
lymphadenopathy specified a hypoechoic pattern, a spherical contour, the 
presence of a distinct border, and a short axis diameter of 6 mm or more. 
Proximal and distal disease lengths were measured in centimetres by reference 
to the incisor teeth. The maximum tumour thickness was measured in millimetres 
with electronic callipers using the EUS software (Key Med). All EUS examinations 
were performed in a single centre by 3 specialist MDT clinicians. 
 
2.3.4 EDTV calculation 
The EDTV was calculated as the maximum potential cylinder volume of disease 
using the formula πr2L where r = tumour thickness and L = total length of disease 
including proximal and distal lymph node metastases as described previously 
(Twine et al. 2010). Although r was measured in millimetres, it was converted to 
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centimetres for calculation. All the EUS data were recorded in a structured EUS-
reporting database. 
 
2.3.5 Treatment 
Patients were selected for radical treatment (surgery or definitive 
chemoradiotherapy) based on perceived radiologic stage, comorbidity and patient 
choice according to algorithms described previously (Crosby et al. 2004; 
Stephens et al. 2006; Gwynne et al. 2011)  
 
2.3.6 Follow-up evaluation 
Patients were reviewed every 3 months for the first year, then every 6 months 
thereafter. One hundred and forty-eight patients were followed up for at least 1 
year or until death. No patients were lost to follow-up. Death certification was 
obtained from the Office for National Statistics.  
 
2.3.7 Statistical analysis 
Grouped data were expressed as median (range) and non-parametric methods 
used throughout. Correlation was assessed using Spearman’s rho. Cumulative 
survival was calculated by the life table method of Kaplan and Meier. Cox 
proportional hazards regression was used to assess the prognostic value of 
individual variables. Data analysis was carried out with the Statistical Package for 
Social Sciences (SPSS) version 18 (SPSS, Chicago, IL, USA). 
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2.4 RESULTS 
Between January 2009 and November 2011, 185 patients with potentially curable 
OC underwent PET/CT and EUS. Thirty-two patients (17.3%) had tumours which 
were not traversable on endoscopic assessment, but 3 patients underwent 
successful dilatation prior to EUS. Tumour thickness was not measured if 
tumours were not traversed. The median SUVmax was similar between patients 
who had traversable and non-traversable tumours (8.7 versus 10.0, p=0.124). 
Although the median SUVmax in the first centre was lower than the second centre, 
this difference was not statistically significant (8.1 versus 10.1, p=0.056). 
 
All patients were analysed according to an intention-to-treat basis (Table 2.1) of 
whom 83 underwent surgery (58 neoadjuvant chemotherapy; 25 Ivor Lewis 
oesophagectomy, 25 transhiatal oesophagectomy, four three-stage 
oesophagectomy, 13 total gastrectomy and 16 open and close laparotomy), 46 
definitive chemoradiotherapy, three endoscopic mucosal resection and 53 
received palliative therapy.       
 
Of the 53 patients who received palliative therapy, 25 patients were up-staged by 
PET/CT detected distant metastases, and 16 patients were found to have 
inoperable tumours at EUS, five patients had liver or peritoneal metastases on 
staging laparoscopy that were not picked up on radiological imaging, and seven 
patients were found to be unfit for curative treatment on CPX.  Fifty-five patients 
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were upstaged by the combination of EUS and PET/CT (Table 2.2).  A higher 
SUVmax was associated with more advanced disease (p<0.0001, Table 2.4). 
 
2.4.1 Utility of SUVmax and correlation with EDTV 
Ninety-one percent of patients (168/185) had FDG-avid tumours on PET/CT. A 
high SUVmax was associated with advanced overall radiological stage but not sex, 
age or histological subtype (Table 2.4). The median SUVmax and EDTV was 8.9 
(0-50) and 48.0 (0.28-547.46) cm3 respectively. A scatter plot of SUVmax related to 
EDTV is illustrated in Figure 2.1. There was a positive and significant correlation 
between SUVmax and EDTV (Spearman’s rho=0.339, p=0.001). This correlation 
was stronger compared to the correlation between SUVmax and EUS-defined total 
length of disease (Spearman’s rho=0.112, p=0.08). 
 
2.4.2 Recurrence rates 
The median SUVmax in patients who developed locoregional, distant or 
locoregional and distant recurrence was 7.4, 9.3, 14.9 respectively (p=0.424). 
Overall recurrence rates were higher in patients who had undergone definitive 
chemoradiotherapy when compared with patients who had undergone surgery 
(p=0.055, Table 2.3). 
.    
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2.4.3 Duration of survival 
Univariate analysis 
Cumulative survival was significantly better in patients with lower SUVmax (2 year 
survival 55% for SUVmax <8.9 versus 34% for SUVmax ≥8.9, p=0.002, Fig.2.2) and 
lower EDTV (2 year survival 79% for EDTV <48.0cm3 versus 37% for EDTV 
≥48cm3, p=0.001, Fig.2.3). Cumulative survival related to PET/CT N Stage is 
shown in Figure 2.4 (2 year survival was 58%, 31%, 26% and 0% in N0, N1, N2 
and N3 respectively, p<0.0001). All factors associated with survival on univariate 
analysis are shown in Table 2.5.  
 
In a subgroup analysis of patients who underwent surgical resection, the median 
SUVmax and EDTV was 7.8 (0 – 36) and 39.0 (0.38 – 343.58) cm
3 respectively. 
The median SUVmax was significantly lower in patients who underwent surgery 
when compared to patients who did not (7.8 vs. 10.9, p=0.007). However, the 
median EDTV was similar irrespective of treatment types (39.0 versus 58.0 cm3, 
p=0.216). Cumulative survival in this subgroup of patients was not associated 
with SUVmax but was associated with EDTV (2 year survival 85% for EDTV <39.0 
cm3 versus 57%, for EDTV ≥39.0 cm3, p=0.001).  
 
Multivariate analysis 
The factors found to be significantly associated with survival on univariate 
analysis (Table 2.5) were entered into a multivariate analysis using Cox’s 
proportional hazards model, the results of which are shown in Table 2.6.  
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Table 2.1 Demographic details of 185 patients included in study 
 
Age, years (range)    66 (35-82) 
Sex, male:female (%)   131:54 (71:29) 
Tumour location (%)   
 Middle third oesophagus   38 (20.6) 
 Distal third oesophagus  81 (43.8) 
 Oesophagogastric junction  66 (35.7) 
   Siewert type I 13 (19.7) 
   Siewert type II 16 (24.2) 
   Siewert type III 37 (56.1) 
Histology (%) 
 Adenocarcinoma   139 (75.1) 
 Squamous cell carcinoma  46 (24.9) 
Median SUVmax (range)   8.9 (0-50)  
EUS tumour length, cm  
Mean (range)   6.88 (1-20) 
 Median    6.00 
 Standard deviation   3.88 
Median EDTV, cm3 (range)  48 (0.28-547.46)  
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Table 2.2  Overall CT and combined radiological stage of all patients  
 
    Overall Radiological Stage (EUS/PET/CT) 
Overall CT Stage I  II  III  IV  Total 
  I 25  5  2  3  35 
  II 0  44  15  8  67 
  III 0  0  61  22  83 
Total   25  49  78  33  185 
 
Table 2.3  Recurrence rates related to treatment type 
            
    Surgery CS  dCRT  p value 
Total number  25  58  46 
Recurrence rates (%)      0.055 
Local    1 (4)  6 (10)  8 (17)   
Distant   0  4 (7)  8 (17) 
Local & distant  0  2 (3)  5 (11) 
 
CS – Neoadjuvant chemotherapy followed by surgery; dCRT – definitive 
chemoradiotherapy 
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Table 2.4  Median SUVmax related to sex, age, histological type and overall 
combined radiological stage of patients with oesophageal cancer  
   
     Median SUVmax  p value 
Sex         0.183 
 Male     8.6 
 Female    10.3  
Age, years        0.07 
 <50     8.1 
 50-59     8.5 
 60-69     11.2 
 >70     8.7 
Histology         0.171 
 Adenocarcinoma   8.5 
 Squamous cell carcinoma  10.5 
Overall radiological stage       <0.0001 
 Stage I    3.8 
 Stage II    8.7 
 Stage III    9.4 
 Stage IV    13.2 
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Table 2.5  Univariate analysis of factors associated with survival 
 
Factors   Log Rank  df   p value 
PET/CT LNMC  33.684  7  0.015 
PET/CT SUVmax   9.164   1  0.002 
EUS N stage   14.613  3  0.002 
ELoD    10.464  1  0.001 
EDTV (<48 vs. ≥48cm3) 11.93   1  0.001 
PET/CT N stage  24.285  3  <0.0001 
EUS LNMC   133.535  12  <0.0001 
 
Table 2.6  Multivariate analysis of factors associated with survival 
  
Factors   Hazard ratio  95% CI  p value 
EDTV (<48 vs. ≥ 48cm3) 3.118    1.357-7.167  0.007 
PET/CT N0   Reference  group    0.022   
PET/CT N1   0.255   0.084-0.698  0.007 
PET/CT N2   0.496   0.159-1.577  0.201 
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Figure 2.1 Scatter plot of SUVmax and EDTV  
 
 
 
Spearman’s rho = 0.339, p = 0.001 
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Figure 2.2  Kaplan-Meier survival plot related to SUVmax  
 
 
 
Caption 
Numbers at risk 
<8.9       74  67      59  49      44  35  
≥8.9      87  70      52  39      30  9  
— =  <8.9   ----- = ≥8.9   
Log rank = 9.164, df. 1, p=0.002  
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Figure 2.3  Kaplan-Meier survival plot related to EDTV. 
 
 
Caption 
Numbers at risk 
<48cm3   54  53      49  43      43  37  
≥48cm3   49  45      34  25      18  13  
— =  <48cm3   ----- = ≥48cm3    
Log rank = 11.930, df. 1, p=0.001  
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Figure 2.4  Kaplan-Meier survival plot related to PET/CT N stage. 
 
Caption 
Numbers at risk 
N0     119  105      74  36      19  4  
N1     44  35      20  8      2  0 
N2     18  14      5     1      1  0  
N3     4  2      1  0      0  0 
----- =  N0   = N1  -  -  -  - = N2  - - - - - = N3     
Log rank = 24.285, df. 3, p<0.0001  
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2.5 DISCUSSION 
This is the first study to demonstrate a positive and significant correlation 
between PET/CT derived SUVmax and EDTV, which is an independent predictor 
of survival in patients with oesophageal cancer. A larger SUVmax was associated 
with more advanced radiological stages of disease and poorer durations of 
survival on univariate analysis. In keeping with previous reports, 14% of patients 
(26 / 185) were up-staged after PET/CT (Allum et al. 2011; Gillies et al. 2011). 
 
Reports on the prognostic significance of PET/CT derived SUVmax have been 
equivocal. A meta-analysis of 10 studies which included 542 patients with OC 
reported that a high pre-treatment SUV was predictive of poor survival (Pan et al. 
2009). However, the SUV threshold in the studies ranged from 3 to 15 which 
were based on the median SUV. This wide range of SUV could be explained by 
the inclusion of patients of different stages and histological subtypes as the 
SUVmax for adenocarcinomas are significantly lower than those for squamous cell 
carcinomas, as expected from the inherent biological variation (Gillies et al. 
2011). However, this difference in SUVmax was not observed in the present study.  
 
A recent report of 121 patients with oesophageal adenocarcinoma who had 
received neoadjuvant chemotherapy followed by surgery reported that the 
presence of FDG-avid lymph nodes, but not SUVmax was an independent adverse 
prognostic indicator (Gillies et al. 2012). This could be due to the fact that 
patients with metastatic disease who had tumours with higher SUVmax were 
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excluded from the analysis. These patients were staged using TNM6 edition 
(Sobin et al. 2002) whereby the N stage was a dichotomous variable which is not 
as accurate at predicting prognosis when compared with TNM7 (Reid et al. 
2011). Choi et al. reported a cohort study of 69 patients with oesophageal 
squamous cell carcinoma and demonstrated that the number of PET-positive 
lymph nodes was an independent predictor of survival (Choi et al. 2004). 
However, the number of lymph nodes in that study was not analysed as a 
continuous variable but rather categorised into 0, 1, 2 and ≥3 nodes, and the N 
stage was analysed as a dichotomous variable. Although the number of PET-
positive lymph nodes when analysed as a continuous variable in this study was 
significant on univariate analysis, only TNM7 PET/CT defined N stage was found 
to be an independent predictor of survival together with EDTV. 
 
This study had several potential limitations. The tumour volume calculated in this 
study was arguably an overestimate of the true disease volume as it was 
assumed that the tumour thickness was the same throughout the length of the 
tumour. However, this overestimation was potentially negated by the fact that 
tumour thickness in patients with suspicious lymph nodes lying beyond the 
maximum tumour thickness was not included in the assessment of tumour radius 
or diameter. Despite these limitations, EUS-defined total lengths of disease and 
tumour volume have been reported to be independent and significant predictors 
of survival (Twine et al. 2010; Davies et al. 2012). Although the EUS-defined 
tumour thickness was measured to the nearest millimetre, the EUS-defined 
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length of disease was measured to the nearest centimetre, and was therefore 
arguably less accurate. Another potential weakness of this study was that the 
PET/CT examinations were performed at two centres using different machines, 
protocols and uptake times. Although the SUVmax was not standardised between 
the centres, there was no significant difference in SUVmax. Moreover, SUVmax and 
PET/CT N stage were still predictive of survival within the pooled data on 
univariate analysis suggesting that these are prognostically important variables. 
Thirty-two patients with Siewert type III oesophagogastric junctional cancer were 
included because of concern regarding proximal extension of the tumour. The 
SUVmax of these patients was similar to the overall cohort and tumour site was not 
associated with prognosis.  
 
Conversely, the strengths of the study are that the data was collected 
prospectively, from a well-defined geographical area served by an established 
regional upper GI network with a referral base of over 400 upper GI cancer cases 
per year, generating in excess of 100 potentially curative oesophagogastric 
resections. The study’s survival and prognostic data are especially robust 
because no patients were lost to follow-up, and causes and exact dates of death 
were obtained from death certificates provided by the Office for National 
Statistics. Moreover, all EUS examinations and measurements were performed 
by three specialist clinicians with published user reliability (Bowrey et al. 1999; 
Weaver et al. 2004).  
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The accuracy and prognostic significance of various tumour characteristics 
determined by PET/CT including tumour length and total length of disease have 
yet to be determined. Moreover, PET/CT can estimate metabolic disease volume 
using various methods and is currently being assessed as a tool for planning 
treatment in oesophageal cancer (Mamede et al. 2007; Guha et al. 2008).  
Tumour volumes calculated by PET/CT are arguably more accurate when 
compared with EDTV as it follows the contours of the tumour without assuming a 
cylindrical volume. A prospective comparison between these two modalities and 
their relative prognostic significance is therefore warranted.  
 
2.6 CONCLUSION 
Despite improvements in technology, EUS remains an important part of the 
oesophageal cancer staging protocol, and the results of this study reinforce the 
need for total length of disease to be considered and included in standardised 
radiological EUS reports. Although SUVmax was not an independent predictor of 
survival on multivariate analysis, EDTV and PET/CT N stage, as defined by 
TNM7, were important prognostic indicators and further research is needed to 
identify critical prognostic values. This would facilitate the development of risk 
stratification groups which would allow targeted optimum treatment strategies. 
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Chapter 3 
 
 
 
Influence of a regional centralised upper gastrointestinal cancer service  
model on patient safety, quality of care and survival 
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3.1  SUMMARY 
The aim of this study was to determine outcomes of a reconfigured centralised 
upper gastrointestinal (UGI) cancer service model, allied to an enhanced 
recovery programme, when compared with historical controls in a UK cancer 
network. 
 
Details of 606 consecutive patients diagnosed with UGI cancer were collected 
prospectively and outcomes before (n=251) and after (n=355) centralisation 
compared. Primary outcome measures were rates of curative treatment intent, 
operative morbidity, length of hospital stay, and survival.  
 
The rate of curative treatment intent increased from 21 to 36% after centralisation 
(p<0.0001). Operative morbidity (mortality) and length of hospital stay before and 
after centralisation were 40% (2.5%) and 16 days, compared with 45% (2.4%) 
and 13 days respectively (p=0.024). Median and 1 year survival (all patients) 
improved from 8.7 months and 39.0%, to 10.8 months and 46.8%, respectively, 
after centralisation (p=0.032). On multivariate analysis, age (hazard ratio (HR) 
1.894, 95% CI 0.743-4.781, p<0.0001), centralisation (HR 0.809, 95%CI 0.668-
0.979, p=0.03), and overall radiological TNM stage (HR 3.905, 95% CI 1.413-
11.270, p<0.0001) were independently associated with survival. These outcomes 
confirm the patient safety, quality of care, and survival improvements achievable 
by compliance with NHS Improving Outcomes Guidance. 
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3.2  INTRODUCTION 
National Health Service reconfiguration driven by Improving Outcomes Guidance 
has to date resulted in 41 specialist centres providing upper gastrointestinal (UGI) 
cancer care in England and Wales (Allum et al. 2011), and the Association of 
Upper Gastrointestinal Surgeons (AUGIS) has recommended that such units 
should consist of 4 to 6 surgeons, each performing a minimum of 15 to 20 
resections per year and serving a population of 1 to 2 million (AUGIS 2011). In 
2007, 19 of 31 cancer networks in England were reported to have undergone 
reconfiguration and centralisation (Palser et al. 2009) yet progress in Wales has 
received less resources and support. Indeed, the most recent audit of activity 
related to oesophagogastric management demonstrated that many surgeons’ 
case loads remained small, staging strategies were idiosyncratic, operative 
mortality was 12%, and 2 year survival was 42% (Pye et al. 2001) after curative 
surgery compared with 6% and 75% in England (Sue-Ling et al. 1993).  
 
Specialist multidisciplinary team (MDT) expertise has been reported sporadically 
to improve patient outcomes (Sue-Ling et al. 1993; McCulloch 1994; Stephens et 
al. 2006), but these hypotheses have not been tested by means of randomised 
control trials. Moreover, although case volume per surgeon (or unit) has also 
been reported to be an important factor determining short-term treatment 
outcomes of several cancers (Matthews et al. 1986; McCulloch 1994; Steele 
1996; Swisher et al. 2000; van Lanschot et al. 2001; Bachmann et al. 2002; 
Birkmeyer et al. 2003; Skipworth et al. 2010; Anderson et al. 2011), data 
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regarding the factual impact of reconfigured centralised cancer surgery on 
survival is thin and often conflicting (Al-Sarira et al. 2007; Thompson et al. 2007; 
van de Poll-Franse et al. 2011; Boddy et al. 2012; Coupland et al. 2013).  
 
The aim of this study was to determine the influence of a new clinical model of 
care comprising reconfigured centralised surgery, allied to an enhanced recovery 
programme, when compared with the historical control outcomes of three local 
hospital trusts over the previous year. The setting was a UK regional cancer 
network serving a population of 1.4 million.    
 
3.3  METHODS 
3.3.1 Patient selection 
The South East Wales cancer network serves a population of approximately 1.4 
million, and encompasses three NHS Health Boards; Cardiff and Vale University 
Health Board (C&V UHB, catchment population 450,000), Aneurin Bevan Local 
Health Board (AB LHB, catchment population 600,000) and Cwm Taf Local 
Health Board (CT LHB, catchment population 325,000).  Together these LHBs 
are responsible for six acute hospitals; four district general hospitals and two 
teaching hospitals. Before August 2010, the surgical care of patients with 
oesophagogastric cancer was delivered by eight surgeons undertaking surgery at 
four different hospital sites. An agreement was reached in December 2009 to 
reconfigure and centralise the UGI surgical service on a single site at the 
University Hospital of Wales, Cardiff, with an agreed start date of 1 August 2010. 
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The new model was based on five specialist UGI surgeons carrying out all of the 
resectional surgery; three of the surgeons were based at the surgical centre, 
whereas the other two were to operate on an in-reach basis, with a facility for 
joint consultant operating, where necessary. Diagnosis and staging continued to 
be undertaken locally within each health board, co-ordinated via three local 
weekly MDT meetings, and all cases deemed suitable for curative treatment were 
discussed at a weekly regional network South East Wales MDT at Velindre 
hospital. Specific additional changes at the Royal Gwent Hospital, Newport, 
included a two-fold increased frequency of local MDT meetings from fortnightly to 
weekly, and the establishment of a dedicated UGI cancer outpatient clinic, 
serviced by one of the Cardiff-based surgeons. Integral to the new surgical model 
was the establishment of an enhanced recovery programme based on the 
established principles introduced by Kehlet and colleagues in the arena of 
colorectal surgery (Basse et al. 2000).  
 
The oesophageal and gastric cancer caseload referred to the MDTs during the 
year preceding the start of centralisation (August 2009 to July 2010) was 
compared with the following year (August 2010 to July 2011).  Pre-centralisation 
data across the three health boards were collected using a combination of a 
prospectively maintained database (for two of the three health boards; C&V and 
CT) in combination with MDT records and retrospective review of hospital 
records. Measures of outcome included postoperative morbidity and mortality, 
length of hospital stay and survival, one year from diagnosis. No patients were 
55 
 
lost to follow-up and dates and causes of death were obtained by the Wales 
Cancer Intelligence and Surveillance unit from the Office for National Statistics. 
Informed consent was obtained from all patients and ethical approval was sought 
from the regional ethics committee, but a formal application was deemed 
unnecessary. 
 
3.3.2 Surgical treatment and neoadjuvant therapy 
All patients had management plans individually tailored according to factors 
relating to both the patient and their disease. Staging was by means of computed 
tomography, endoscopic ultrasound, computed tomography positron emission 
tomography and staging laparoscopy as appropriate.  The South East Wales 
MDT treatment algorithms for oesophageal and gastric cancer have been 
described previously (Lewis et al. 2002; Morgan et al. 2009). Operative morbidity 
was graded in accordance with the Dindo-Clavien classification (Dindo et al. 
2004). Particular emphasis was placed on the incidence of morbidity of Dindo-
Clavien grade III or higher, as this represented a complication requiring 
endoscopic, radiological or surgical intervention, in contrast with morbidity of 
lower grade requiring only pharmacological treatment. Definitive 
chemoradiotherapy was offered to patients with localised squamous cell 
carcinoma, and patients with adenocarcinoma deemed unsuitable for surgery 
because of disease extent and/or medical co-morbidity (Gwynne et al. 2011; 
Gwynne et al. 2013)  
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3.3.3 Data analysis  
Grouped data were expressed as median (range) and non-parametric statistical 
methods were used.  Continuous data were compared using the Mann Whitney 
test and categorical data using the Chi Square test and Fisher’s exact test when 
number of events was low. StataCorp LP was used to analyse the survival 
information.  A nonparametric two-sample test on the equality of medians was 
carried out. This tested the null hypothesis that pre-centralisation and post-
centralisation patients were drawn from populations with the same median. A 
Log-rank test was performed to determine the equality of the survivor functions. 
Proportional hazard plots were created and Schoenfeld residuals were calculated 
to confirm that the proportional hazard assumption was appropriate for overall 
survival. Differences were deemed to be statistically significant when the p value 
was less than 0.05.  
 
3.4 RESULTS 
The global caseloads of UGI cancer presenting to the regional MDTs were 251 
and 355 patients for the years before and after centralisation, respectively. Table 
3.1 shows the demographic details and treatment of the patients. There were 153 
and 189 deaths at one year before, and after centralisation respectively. All 
patients were followed-up for at least one year or until death. The median follow-
up for all patients and patients who remained alive were 9.8 and 23 months 
respectively. 
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3.4.1 Details of the treatment 
Treatment intent was potentially curative in 54 (21%) and 127 (36%) patients 
before and after centralisation respectively (Chi2=14.91, DF=1, p<0.0001), of 
whom 40 and 85 patients underwent surgery. Of those patients treated surgically, 
19 and 33 underwent oesophagectomy, and 14 and 38 underwent gastrectomy 
before and after centralisation respectively. The rates of open and close 
laparotomy were similar at 7 (18%) and 14 (16%) before and after centralisation 
respectively (Chi2=0.063, DF=1, p=0.801). The number of patients undergoing 
palliative chemotherapy increased from 84 (43%) to 135 (59%) (Chi2=11.62, 
DF=1, p=0.001) 
 
3.4.2 Operative Morbidity and Mortality 
Short term surgical outcomes and duration of hospital stay data are presented in 
Table 3.2. The cause of the in-hospital death before centralisation was 
myocardial infarction following total gastrectomy. The causes of the two in-
hospital deaths after centralisation were multi-organ failure secondary to conduit 
necrosis following trans-thoracic oesophagectomy, and intra-abdominal sepsis 
following subtotal gastrectomy. Morbidity is presented related to Dindo-Clavien 
classification.  There were non-significant 50% reductions in the incidence of 
serious (Dindo-Clavien ≥ III) morbidity for all the surgical patients. Anastomotic 
leaks occurred in two (5.0%) and six (7.1%) of patients before and after 
centralisation, respectively. 
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3.4.3 Duration of hospital stay 
Centralisation was associated with a significant reduction in intensive therapy unit 
(ITU), (p<0.0001) and critical care (p=0.002) lengths of stay for all patients.  The 
median overall length of hospital stay was shortened by three days (p=0.024). 
The 30-day hospital re-admission rates were 5.1% (n=2) and 11.8% (n=10) 
before and after centralisation, respectively (p=0.275). Of the 10 patients who 
were re-admitted after centralisation (pneumonia = 3; intra-abdominal collection = 
2; dysphagia = 1; thoracic incisional hernia = 1; wound infection = 1; chyle leak = 
1; pancreatitis = 1), six were from AB LHB, one of whom had to be readmitted to 
the University Hospital of Wales for conservative management of a chyle leak. 
The remaining five patients were admitted to their local district general hospitals 
for medical management.  
 
3.4.4 Duration of overall survival 
Centralisation was associated with a significant increase in overall median and 
one year survival in all patients, 8.7 versus 10.8 months (p=0.011) and 39.0% 
versus 46.8%, respectively (Figure 3.1). In patients with oesophageal and gastric 
cancer, the median and one year survival was higher following centralisation 
although this was not statistically significant [oesophageal cancer: 8.7 versus 
10.3 months, 38.9% versus 44.0%, p=0.139; gastric cancer: 7.7 versus 12.5 
months, 39.3% versus 51.1%, p=0.065).  
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3.4.5 Factors influencing overall survival 
The univariate analysis of factors influencing overall survival is shown in Table 
3.3. All factors found to be significant on univariate analysis were included in the 
multivariate analysis. Backward elimination stepwise regression was carried out 
to determine the best model, and as treatment intent was no longer significant it 
was excluded from the final model (Table 3.4).  
 
3.4.6 Caseload 
After centralisation, the proportion of operations performed with a team of two 
consultants increased from 2.5% (1/40), to 59% (50/85) (Chi2=28.26, DF=1, 
p<0.0001). This led to an increase in the median number of operations performed 
per surgeon from four (2-11) to 23 (16-31) (p<0.0001).   
 
3.4.7 Access to the designated surgical centre 
Patient satisfaction was assessed and feedback obtained from 85 patients who 
had surgery after centralisation via a postal questionnaire three months after 
surgery. The response rate was 68% (58/85, 18 from C&V, 23 from AB and 17 
from CT). Overall patient satisfaction was assessed using a Likert scale from 0 
(least satisfied) to 10 (most satisfied), and the median satisfaction score was 9.6 
(5-10). Forty-six patients (79.3%) were content to travel for treatment at the 
designated treatment centre at the University Hospital of Wales, Cardiff. Of the 
12 patients who cited access difficulties, six (50%) were from CT, five (41.7%) 
from AB, and one (8.3%) from C&V. 
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Table 3.1 Demographic details and treatment of the patients pre- and post-
centralisation 
    Pre-centralisation Post-centralisation  p-value 
Total    251   355 
Median age (range), yrs 74 (32-97)  71 (33-95)  0.007 
Male:Female   166:85 (66:34) 231:124 (65:35) 0.813 
Oesophageal:Gastric 139:112 (56:44) 216:139 (61:39) 0.197 
Radiological Stage  I 26 (10)  34 (10)  0.973 
          II 40 (16)  53 (15) 
   III 78 (31)  107 (30) 
   IV 97 (39)  144 (40) 
         Not staged 10 (4)   17 (5) 
Curative:Palliative treatment  
 Total   54:197 (21:79) 127:228 (36:64) <0.0001 
 Oesophageal 33:106 (24:76) 76:140 (35:65) 0.023 
 Gastric  21:91 (18:82) 51:88 (37:63) 0.002 
dCRT    12 (5)   32 (9)   0.056 
Neochemo   17 (43)  48 (56)  0.351 
Surgery   40 (16)  85 (24)  0.005 
Palliative chemotherapy 84 (43)  135 (59)  0.001 
 
Figures are numbers (%).  Neochemo – neoadjuvant chemotherapy, dCRT – 
Definitive chemoradiotherapy 
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Table 3.2 Short-term surgical outcomes  
 
   Pre-centralisation Post-centralisation p value 
Number  40   85 
Morbidity and mortality 
All morbidity  16 (40)  38 (45)   0.681 
Morbidity of Dindo- 10 (25)  10 (12)   0.0062 
Clavien Grade≥III 
30 day mortality 1 (2.5)   1 (1.2) 
In-hospital mortality 1 (2.5)   2 (2.4) 
Length of stay 
ITU stay  0 (0-70)  0 (0-12)   <0.0001 
HDU stay  1 (0-11)  1 (0-9)   0.043 
Critical care stay 2 (0-70)  1 (0-20)   0.002 
Total hospital stay 16 (2-72)  13 (3-49)   0.024 
 
Figures are numbers (%). Lengths of stay are median in days (range) 
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Table 3.3 Univariate analysis of factors associated with overall survival 
 
Factor   Hazard Ratio 95% CI  p value 
Age ≤50       
Age 51-60   1.1867  0.7094-1.9852 0.514 
Age 61-70   1.4361  0.9024-2.2854 0.127 
Age 71-80   1.503   0.9498-2.3787 0.082 
Age >80   2.5113  1.5834-4.0053 <0.0001 
    
Pre-centralisation  1.0000   
Post-centralisation  0.7851  0.6506-0.9474 0.012 
   
CT Stage 1   1.0000   
CT Stage 2   2.4182  1.4015-4.1722 0.002 
CT Stage 3   3.7373  2.2532-6.1989 <0.0001 
CT Stage 4   7.9656  4.8451-13.0958 <0.0001 
 
Non curative   1.0000 
Curative   0.1821  0.1396-0.2376 <0.0001 
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Table 3.4 Multivariate analysis of factors associated with overall survival  
       
Factor   Hazard Ratio 95% CI  p-value 
    
Age ≤50   1.0000   
Age 51-60   1.2488  0.743-2.100  0.402 
Age 61-70   1.4816  0.929-2.363  0.099 
Age 71-80   1.8944  1.193-3.009  0.007 
Age >80   2.9749  1.851-4.781  <0.0001 
    
Pre-centralisation  1.0000   
Post-centralisation  0.8090  0.668-0.979  0.030 
   
rTNM Stage I  1.0000   
rTNM Stage II  2.4384  1.413-4.207  0.001 
rTNM Stage III  3.9051  2.353-6.480  <0.0001 
rTNM Stage IV  8.8962  5.403-14.647  <0.0001 
 
rTNM – Radiological overall TNM Stage 
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Figure 3.1 Kaplan-Meier survival plot related to centralisation  
 
 
Numbers at risk  
Time (months)  
0  3             6    9       12 
Pre  251        199              151    120                98  
Post 355      289              235      200            166  
 
Log-rank test for equality of survivor functions: 
Chi2 = 6.41  p value = 0.0113 
______  Pre-centralisation  - - - - - - Post-centralisation 
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3.5 DISCUSSION 
UGI cancer service development and configuration in the UK remains 
controversial and opinion polarised. The principal findings of this study were that 
centralisation was feasible and safe. The curative to palliative treatment ratio 
increased by 71%, operative morbidity fell 50%, lengths of hospital stay reduced 
on average by three days, median survival improved by 20%, and overall one 
year survival improved by nearly 20%. 
 
The strengths of this study are that it represents, by some margin, the largest of 
very few UK reports regarding UGI cancer service centralisation, relating to 606 
consecutive patients presenting to a single UK regional cancer network. Data 
were collected prospectively at all local and regional MDT meetings over a period 
of two years; data on readmission to hospital was complete, survival data is 
particularly robust because no patients were lost to follow up, and death 
certification was obtained from the Office of National Statistics. At the time of 
writing, only three other UK centres have reported their experience of centralising 
oesophagogastric cancer surgery. Branagan and Davies reported outcomes from 
the Wessex region in 2004. Although the number of patients treated was 
relatively modest, operative mortality decreased significantly from 15.2% to zero 
(5 of 33 versus 0 of 40, p=0.022), pathology reports improved, and mean lymph 
node harvest increased from 19 to 30.5 after centralisation (Branagan et al. 
2004). Forshaw et. al. reported a larger experience of oesophagogastric 
resection from a high volume unit in London (Forshaw et al. 2006). Thirty day 
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mortality was 0.5% and one year survival was 78%, without detrimental effect on 
the benign elective workload. The findings of this study are in keeping with the 
above in terms of cancer management, although with 65% of theatre capacity 
used wholly or in part for cancer surgery, there will arguably have been an 
associated impact on the benign UGI work stream. More recently, Boddy et. al. 
reported an improved median survival after centralisation in Gloucestershire in 
2006 (Boddy et al. 2012). However, this improvement was only observed after 
oesophagectomy, and the study was retrospective in nature without detailed 
follow-up data.  
 
In contrast, the study has a number of potential limitations. The data related to 
surgical outcomes in historical control patients was collected retrospectively from 
one hospital site (40%, 16/40), and arguably may be less robust than that 
collected prospectively the following year, as the value of retrospective case note 
review depends on accurate contemporaneous documentation at presentation. 
However, this is mitigated by two factors; first, data were collected prospectively 
on all patients undergoing surgery before centralisation from two of the three 
health boards (60%, 24/40); second computerised digital records at the remaining 
health board recorded all radiological and pathological test results, operation 
notes, and discharge documentation. It is therefore unlikely that major errors 
existed related to outcomes and in particular hospital length of stay. The rise in 
the number of patients following centralisation may arguably be due to more 
accurate prospective data capture, allied to a detailed reconfigured service 
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evaluation that included a dedicated research fellow in attendance at all local and 
regional MDT meetings. Before centralisation, it is possible that some equivocal 
palliative cases may have bypassed MDT discussion, as MDT meetings in one 
LHB were held less frequently (fortnightly). Definition of the case subjects and of 
the controls is critical in determining outcomes and subsequent conclusions, and 
in this study centralisation inception after on August 1st 2010 was chosen. In 2009 
and 2010, the same five surgeons were in surgical practice on two hospital sites, 
but without guaranteed consultant colleague support in theatre to facilitate team 
operating. Two surgeons from AB LHB chose not to take part in the reconfigured 
model and relinquished MDT participation. Moreover, the improved outcomes 
cannot be explained by poorer than average results in our historical control 
group, as outcomes in the year prior to centralisation were comparable with those 
reported in the national (NOGCA 2011).  
 
The exact explicit reason for the improved outcomes witnessed remains 
uncertain. The probable answer lies in a combination of small incremental 
improvements in service, such as the increased frequency of local MDT 
meetings, increased caseload, single centre surgery by teams of surgeons, allied 
to the benefits associated with an enhanced recovery programme, and akin to 
those described in lower gastrointestinal surgical models. Certainly, there is a 
wealth of evidence in support of case volume outcome interactions from 
international population based studies (Matthews et al. 1986; Swisher et al. 2000; 
van Lanschot et al. 2001; Bachmann et al. 2002; Birkmeyer et al. 2003; 
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Birkmeyer et al. 2007; Skipworth et al. 2010; Anderson et al. 2011; van de Poll-
Franse et al. 2011), and more recently data from the Netherlands has reported 
that the type of hospital in which oesophagogastric resectional surgery is carried 
out influences outcomes (Dikken et al. 2012). These benefits must be weighed 
against potential disadvantages, such as downgrading district general hospital 
surgical assets (Dickson et al. 2001), and little evidence of survival benefit 
associated with individual surgeon caseload (Gillison et al. 2002; Thompson et al. 
2007), or surgical centralisation (Birkmeyer et al. 2007). The findings of this study 
have shown that serving a population of 1.4 million generated an annual 
caseload of 85 potentially curative resections for five surgeons. The median 
number of operations performed by the individual surgeons over the year 
concerned increased five-fold from four to 23, with 56% performed by consultant 
teams of two. 
 
Patient access to services is crucial, and frequently the focus of the most intense 
political pressure during any health service reconfiguration. In South East Wales 
the new service resulted in longer distances of travel to hospital for a proportion 
of patients, specifically 17 patients from CT LHB, and 23 patients from AB LHB. 
Of these, 11 (27.5%) cited access difficulties (five from AB, and six from CT). 
However, before centralisation, patients often travelled to a specified surgical 
centre within their LHB for surgery, and therefore in most cases the additional 
distance were relatively small, and diagnosis and radiological staging continued 
locally for all. Allied to this issue is the rate of hospital re-admissions which 
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occurred in 10 patients after centralisation, six of whom resided in the catchment 
areas of the outreach hospitals (AB LHB). However, only one patient of the six 
required readmission to the cancer centre and did not report access difficulties. 
Nevertheless, the hospital readmission rate doubled following centralisation, and 
although not statistically significant, will necessitate continued future audit. 
Arguably this finding may be due to the intense scrutiny, and enhanced follow-up 
protocols to which the reconfigured service was subject, allied to prospective data 
collection by a dedicated research fellow.  
 
3.6 CONCLUSION 
Although not a randomised control trial, the results of this study clearly 
demonstrate unequivocally what can be achieved by contemporary specialist 
care in a UK regional cancer network, and highlights the impact of an enhanced 
reconfigured and centralised service model on UGI cancer outcomes. A hybrid 
centralised clinical model of care allied to an enhanced recovery after surgery 
programme were introduced safely and effectively. This model increased the 
proportion of patients receiving potentially curative treatment, reduced serious 
operative morbidity, shortened total length of hospital stay, and improved 
survival, all by significant margins. Further long-term follow-up for five years is 
desirable and necessary to appreciate the full spectrum and magnitude of the 
patient safety, quality, and survival improvements achievable by reconfiguring 
regional UGI cancer services. 
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Chapter 4 
 
 
 
Systematic review and meta-analysis of the influence of human 
epidermal growth factor receptor-2 (HER2) in patients with operable 
oesophageal cancer 
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4.1 Summary 
The prognostic significance of human epidermal growth factor 2 (HER2) 
overexpression in patients diagnosed with oesophageal cancer is controversial. A 
systematic review and meta-analysis was performed to determine the influence of 
HER2 overexpression and amplification on outcomes in operable oesophageal 
cancer .  
 
MEDLINE and Embase (January 1990 to November 2011) was searched for 
translational studies that correlated HER2 expression with survival in operable 
oesophageal cancer. Fourteen studies involving 1464 patients who had 
undergone potentially curative oesophagectomy for oesophageal cancer  [322 
(22%) HER2 positive] were included. Five year mortality was significantly higher 
in HER2 positive patients [odds ratio (OR) 1.43, 95% confidence interval (CI) 
1.01-1.95, p=0.03]. Analysis related to histological cell type demonstrated 
significantly higher 5 year mortality in HER2 positive squamous cell carcinoma 
[OR 2.88, 95% CI 1.34-6.17, p=0.006] and adenocarcinoma [OR 1.91, 95% CI 
1.15-3.17, p=0.01] on sensitivity analysis of higher quality studies. HER2 
overexpression and gene amplification in operable oesophageal cancer was an 
indicator of poor prognosis.  
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4.2 INTRODUCTION 
Each year, 462,000 people are diagnosed worldwide with oesophageal cancer 
resulting in 386,000 deaths (Parkin et al. 2005). The optimal contemporary 
treatment is controversial and opinion divided. In the UK, following the publication 
of the MRC OEO2 trial, neoadjuvant chemotherapy followed by surgery is the 
standard of care for patients with operable oesophageal cancer (MRC 
Oesophageal Cancer Working Group 2002), whereas neoadjuvant 
chemoradiotherapy followed by surgery is the preferred modality in Europe and 
the United States (Ilson 2008). However, overall survival reports remain poor and 
no established global standard for treatment exists. New therapies which target 
specific genetic alterations arguably offer the best chance for improving patient 
survival. 
 
The human epidermal growth factor receptor 2 (HER2) gene is a proto-oncogene 
which is located on chromosome 17q11.2-12 and encodes a transmembrane 
tyrosine kinase receptor which is responsible for cell growth, differentiation, 
migration and apoptosis (Normanno et al. 2005). HER2 is involved in the 
development of numerous types of cancer such as breast, ovarian, pancreatic 
and is overexpressed in up to 20% of gastric cancer patients, conferring a poor 
prognosis (Slamon et al. 1987).  However, reports on the influence of HER2 
overexpression in patients with oesophageal cancer have been equivocal. The 
aim of this study therefore was to perform a systematic review and meta-analysis 
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of the influence of HER2 overexpression on outcomes in patients diagnosed with 
oesophageal cancer.  
 
4.3 METHODS 
4.3.1 Literature search strategy 
A systematic review of published work was conducted according to the Preferred 
Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines 
(Moher et al. 2009). A computerised search of MEDLINE was performed via 
PubMed and Embase from January 1990 to November 2011 using the MeSH 
subject headings: oesophageal neoplasm and human epidermal growth factor 
receptor 2 or HER2 or Neu or HER-2 or c-erbB-2 or c-erbB2 or erbB2 or CD340 
or p185 to identify studies investigating the influence of HER2 protein 
overexpression or gene amplification on survival in patients with oesophageal 
cancer. The searches were limited to human articles published in the English 
language. Further articles were identified by hand searching reference lists of all 
articles retrieved to identify potentially relevant studies. Searches were cross-
referenced on PubMed using the related articles function. The last search date 
was 1 November 2011.  
 
4.3.2 Data extraction 
Data were extracted independently using a standard protocol. The following 
information was extracted from each study: first author, year of publication, study 
design, number of subjects in each group (HER2+ and HER2-), histological 
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subtype (adenocarcinoma or squamous cell carcinoma), use of neoadjuvant 
chemotherapy and or chemoradiotherapy, method of identifying HER2 
expression or gene amplification, quality of study (see below) and outcome 
measures (all-cause mortality).  
 
4.3.3 Inclusion and exclusion criteria 
Translational studies comparing overall survival outcomes in patients with 
operable oesophageal cancer with and without HER2 overexpression or gene 
amplification were included. When there were multiple articles by the same 
authors analysing data from the same or similar patient group, the most recent 
publication was included. Review articles, case reports, experimental studies and 
studies that did not report outcomes were excluded. Unpublished data from 
conference abstracts were excluded. 
 
4.3.4 Statistical analysis 
The meta-analysis was performed in line with the recommendations from the 
Cochrane Collaboration and PRISMA guidelines (Moher et al. 2009) using 
Review Manager 5.1 (The Nordic Cochrane Centre, The Cochrane Collaboration, 
Copenhagen, Denmark). Statistical analysis of dichotomous variables were 
carried out using odds ratio (OR) as the summary statistic. Random-effects 
models were used and were reported with 95% confidence intervals (CI). ORs 
represent the odds of death during the study interval in a patient who was HER2 
positive compared with a patient who was HER2 negative. An OR of less than 1 
75 
 
favoured patients who were HER2 negative and the point estimate of the OR was 
considered significant at the p<0.05 level if the 95% CI did not include the value 
1.  
 
4.3.5 Heterogeneity 
The quality of non-randomised studies was assessed using the Newcastle-
Ottawa scale (Higgins JPT 2009) which examines patient selection methods, 
comparability of study groups and assessment of outcome. A score of at least 7 
stars from a  maximum of 9 were considered to be of higher quality. 
Heterogeneity was assessed by sensitivity analysis, which was undertaken using 
the subgroup studies of higher quality and those reporting outcomes on more 
than 100 patients. The I2 value was reported for each analysis.  
 
4.3.6  Publication bias 
Funnel plots were used to assess bias (Egger et al. 1998). Funnel plot 
asymmetry implied that results were subject to reporting or publication bias, 
whereas symmetry implied a lack of bias.  
 
4.4 RESULTS 
The full text of 37 papers were obtained of which 14 were cohort studies which 
fulfilled the criteria for review (Figure 4.1). Analysis was carried out on 1464 
patients (1149 males, 315 females) who had undergone potentially curative 
oesophagectomy for oesophageal (1221, 83%) and oesophagogastric junctional 
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cancer (243, 17%). Three hundred and twenty-two patients (22%) were HER2 
positive and 1142 were HER2 negative.  
 
Figure 4.1  Identification process for eligible studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
(n=93) 
Records identified through other 
sources 
(n=44: all from references) 
Records after duplicates removed 
(n=88) 
Records screened by abstract 
(n=88) 
Records excluded 
(n=51) 
Full text assessed for eligibility 
(n=37) 
Records excluded (n=23) 
 7 reviews 
16 not meeting inclusion 
criteria 
 
Studies included in meta-analysis 
(n=14) 
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4.4.1 Characteristics of included studies 
All studies included were retrospective cohort studies except for one which was a 
prospective cohort study (Stoecklein et al. 2008). Table 4.1 summarizes the study 
characteristics. Seven studies were of high quality (Nakamura et al. 1994; 
Polkowski et al. 1999; Brien et al. 2000; Stoecklein et al. 2008; Hu et al. 2011; 
Langer et al. 2011; Thompson et al. 2011). Two studies investigated patients with 
oesophageal squamous cell carcinoma only (Mimura et al. 2005; Sato-Kuwabara 
et al. 2009) and eight studies with oesophageal adenocarcinoma (Flejou et al. 
1994; Nakamura et al. 1994; Duhaylongsod et al. 1995; Polkowski et al. 1999; 
Brien et al. 2000; Hu et al. 2011; Langer et al. 2011; Thompson et al. 2011). Four 
studies included both histological types (Hardwick et al. 1997; Friess et al. 1999; 
Reichelt et al. 2007; Stoecklein et al. 2008) of which three (Hardwick et al. 1997; 
Friess et al. 1999; Stoecklein et al. 2008) did not have separate outcomes for 
adenocarcinoma and squamous cell carcinoma. Ten studies included only 
oesophageal tumours and four studies also included oesophagogastric junctional 
tumours (Duhaylongsod et al. 1995; Hardwick et al. 1997; Polkowski et al. 1999; 
Thompson et al. 2011). Survival data for individual tumour sites were not 
available in those studies. Only one study included patients who had undergone 
neoadjuvant chemoradiotherapy (Duhaylongsod et al. 1995). Details of stage of 
disease in HER2 positive and negative patients were described in all but four 
studies (Duhaylongsod et al. 1995; Hardwick et al. 1997; Polkowski et al. 1999; 
Hu et al. 2011). The stage of disease was similar in both groups of patients in all 
studies except for Nakamura et al (Nakamura et al. 1994). HER2 positive patients 
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in that study had a significantly higher proportion of stage IV disease compared 
with HER2 negative patients. However, a correction was applied in the 
multivariate analysis, and HER2 overexpression was an independent predictor of 
poor survival (Nakamura et al. 1994). 
 
4.4.2 Method of evaluation HER2 status 
Immunohistochemistry (IHC) and in-situ hybridisation (ISH) were used to 
determine HER2 overexpression and gene amplification in six (Flejou et al. 1994; 
Nakamura et al. 1994; Duhaylongsod et al. 1995; Hardwick et al. 1997; Friess et 
al. 1999; Polkowski et al. 1999) and five (Brien et al. 2000; Reichelt et al. 2007; 
Stoecklein et al. 2008; Hu et al. 2011; Thompson et al. 2011) studies, 
respectively. Three studies (Mimura et al. 2005; Sato-Kuwabara et al. 2009; 
Langer et al. 2011) used both methods for determining HER2 status. HER2 
positive status was defined using various cut-offs (Table 4.1). HER2 
overexpression was defined according to the intensity of membrane staining [≥+2 
(Nakamura et al. 1994; Friess et al. 1999) and +3 (Sato-Kuwabara et al. 2009; 
Langer et al. 2011)]. HER2 gene amplification was defined as a 
HER2/chromosome 17 ratio of greater than 2 (Sato-Kuwabara et al. 2009; Langer 
et al. 2011), 2.2 (Thompson et al. 2011) and 3 (Reichelt et al. 2007).  Two studies 
had a lower threshold for defining HER2 positivity. Flejou (1994) included all 
patients with any level membrane staining and Polkowski (1999) included 
patients who had membrane staining in at least 5% of tumor cells. HER2 
positivity ranged from 9 to 64%. 
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4.4.3 Short- and long-term survival related to HER2 status 
Seven studies reported a significantly poorer survival in patients who were HER2 
positive (Flejou et al. 1994; Nakamura et al. 1994; Polkowski et al. 1999; Brien et 
al. 2000; Mimura et al. 2005; Sato-Kuwabara et al. 2009; Langer et al. 2011). Six 
studies reported no difference in survival of patients who were HER2 positive or 
negative (Hardwick et al. 1997; Friess et al. 1999; Reichelt et al. 2007; Stoecklein 
et al. 2008; Hu et al. 2011; Thompson et al. 2011). One study reported a higher 
survival in patients who were HER2 positive (Duhaylongsod et al. 1995). One, 
two and five-year survival rates were available in all studies except for two 
studies which did not report five-year survival (Friess et al. 1999; Polkowski et al. 
1999).  
 
4.4.4 Survival in all patients 
In the meta-analysis of all studies, there was a significantly higher 5 year 
mortality rate in patients who were HER2 positive compared with patients who 
were HER2 negative whereas 1 and 2 year mortality rates were not significantly 
different. Sensitivity analysis of higher quality studies and studies with over 100 
patients were similar to the overall analysis.  Heterogeneity between studies of all 
patients was significant at 1, 2 and 5 years (Table 4.2 and Figure 4.2).  
 
4.4.5 Survival in patients with adenocarcinoma 
In the analysis of all studies, there was no significant difference in survival in 
patients diagnosed with HER2 positive adenocarcinoma compared to those who 
were HER2 negative. However, sensitivity analysis of higher quality studies and 
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studies with over 100 patients with adenocarcinoma confirmed the poorer survival 
rate in HER2 positive patients (Table 4.3 and Figure 4.3). Heterogeneity between 
studies of all patients with adenocarcinoma at 5 years was significant (I2 = 73%, 
p=0.0005). The influence of HER2 overexpression and amplification was greater 
when studies which only included oesophageal tumours (excluding junctional 
tumours) were analysed [OR 2.37, 95% CI (1.59-3.54), p<0.0001]. Heterogeneity 
of these studies was not significant (I2 = 41%, p=0.009).  
 
4.4.6 Survival in patients with squamous cell carcinoma 
The influence of HER2 positivity was greater in patients with squamous cell 
carcinoma (Table 4.4 and Figure 4.4) compared to patients with adenocarcinoma. 
Sensitivity analysis of studies involving patients with squamous cell carcinoma 
was not performed due to the small number of studies. There was no 
heterogeneity between studies of patients at 5 years (I2 = 0%, p=0.52). 
 
4.4.7 Publication bias 
The funnel plots for 5 year mortality rate lacked symmetry for all studies, which 
was reflected in the observed heterogeneity (p=0.0002), and may represent 
publication bias. However, the number of studies included (>100 patients) was 
less than 10, making the funnel plot difficult to interpret (Parmar et al. 1998). The 
funnel plots for 5 year mortality rate was asymmetrical for studies of patients with 
adenocarcinoma (heterogeneity p=0.0005) although it was symmetrical for  
studies of patients with squamous cell carcinoma (heterogeneity p=0.52).  
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Table 4.1 Characteristics of studies included in the meta-analysis 
 
 
 
 
 
 
First author (year) Test Classification of 
HER2+ status 
Total 
number 
HER2+ 
(%) 
Survival 
related to 
HER2+ 
Study 
quality 
score 
Brien (2000)  ISH Average number 
of HER2 signals 
63 12 (19) Worse 7 
Duhaylongsod (1995)  IHC N/A 42 18 (43) Better 6 
Flejou (1994)  IHC ‘Membrane 
staining’ 
66 7 (11) Worse 5 
Friess (1999)  IHC ≥ +2 39 25 (64) No 
difference 
6 
Hardwick (1997)  IHC ≥ 10 % of cells 205 49 (24) No 
difference 
6 
Hu (2011)  ISH >10 % of cells 116 21 (18) No 
difference 
7 
Langer (2011)  Both +3 and Ratio ≥ 2 142 41 (29) Worse 8 
Mimura (2005)  Both ≥ +2 66 9 (14) Worse 6 
Nakamura (1994)  IHC ≥ +2 62 8 (13) Worse 7 
Polkowski (1999)  IHC ≥ 5 % of cells 33 9 (27) Worse 7 
Reichlt (2007)  ISH Ratio > 3 255 23 (9) No 
difference 
6 
Sato-Kuwabara 
(2009)  
Both +3 and Ratio > 2 185 68 (37) Worse 6 
Stoecklein (2008)  ISH ≥ 1 tumour cell 
with ‘HER2 gain’ 
101 18 (18) No 
difference 
8 
Thompson (2011)  ISH Ratio > 2.2 89 14 (16) No 
difference 
7 
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Table 4.2 Meta-analysis of the influence of HER2 overexpression/amplification 
on mortality in patients with oeosphageal carcinoma 
 
 
 
 
 
 
 
Outcome No. of 
studies 
HER2
+ 
HER2
- 
OR (95% 
CI) 
Overall 
effect Z 
p 
value 
HG 
I2 
(%) 
HG p 
value 
All studies         
1 year all 
cause mortality  
14 322 1142 0.98 (0.72-
1.32) 
0.16 0.88 61 0.001 
2 year all 
cause mortality 
14 322 1142 1.01 (0.78-
1.31) 
0.09 0.92 68 0.000
1 
5 year all 
cause  mortality 
12 288 1104 1.43 (1.04-
1.95) 
2.23 0.03 69 0.000
2 
         
High quality 
studies 
        
1 year all 
cause mortality  
7 123 483 1.06 (0.68-
1.67) 
0.27 0.79 62 0.02 
2 year all 
cause mortality 
7 123 483 1.41 (0.94-
2.11) 
1.64 0.10
0 
68 0.004 
5 year all 
cause mortality 
6 114 459 1.90 (1.18-
3.05) 
2.65 0.00
8 
72 0.003 
         
Studies with 
>100 patients 
        
1 year all 
cause mortality  
6 220 784 0.95 (0.64-
1.39) 
0.28 0.78 50 0.08 
2 year all 
cause mortality 
6 220 784 0.90 (0.66-
1.22) 
0.69 0.49 44 0.11 
5 year all 
cause mortality 
6 220 784 1.52 (1.05-
2.20) 
2.20 0.03 65 0.01 
83 
 
Table 4.3 Meta-analysis of the influence of HER2 overexpression/amplification 
on mortality in patients with oesophageal adenocarcinoma 
 
 
 
 
 
 
 
Outcome No. of 
studies 
HER2
+ 
HER2
- 
OR (95% 
CI) 
Overall 
effect 
Z 
p 
value 
HG 
I2 
(%) 
HG p 
value 
All studies         
1 year all 
cause mortality  
9 146 573 1.03 (0.69-
1.54) 
0.15 0.88 65 0.004 
2 year all 
cause mortality 
9 146 573 1.21 (0.84-
1.75) 
1.01 0.31 75 <0.00
01 
5 year all 
cause mortality 
8 137 549 1.33 (0.89-
2.00) 
1.38 0.17 73 0.000
5 
         
High quality 
studies 
        
1 year all 
cause mortality  
6 105 400 1.17 (0.72-
1.88) 
0.63 0.53 64 0.02 
2 year all 
cause mortality 
6 105 400 1.64 (1.05-
2.57) 
2.17 0.00
3 
70 0.005 
5 year all 
cause mortality 
5 96 376 1.91 (1.15-
3.17) 
2.50 0.01 78 0.001 
         
Studies with 
>100 patients 
        
1 year all 
cause mortality  
3 78 286 0.85 (0.47-
1.53) 
0.55 0.58 70 0.03 
2 year all 
cause mortality 
3 78 286 1.26 (0.75-
2.12) 
0.89 0.38 52 0.12 
5 year all 
cause mortality 
3 78 286 1.73 (1.01-
2.97) 
1.98 0.05 73 0.02 
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Table 4.4 Meta-analysis of the influence of HER2 overexpression/amplification 
on mortality in patients with oesophageal squamous cell carcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome No. of 
studies 
HER2
+ 
HER2
- 
OR (95% 
CI) 
Overall 
effect 
Z 
p 
value 
HG 
I2 
(%) 
HG p 
value 
All studies         
1 year all 
cause mortality  
3 84 312 2.43 (0.93-
6.37) 
1.80 0.07 6 0.34 
2 year all 
cause mortality 
3 84 312 0.76 (0.45-
1.27) 
1.06 0.29 62 0.07 
5 year all 
cause mortality 
3 84 312 2.88 (1.34-
6.17) 
2.72 0.00
6 
0 0.52 
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Figure 4.2 Influence of HER2 overexpression or amplification on 5 year mortality in  
all patients with oesophageal carcinoma. Weights are from random-effects analysis. 
Squares indicate the point estimates of the effect of disease (odds ratio) and 
diamonds the summary estimate from the pooled studies; 95% confidence intervals 
are indicated by horizontal bars and shown in parentheses 
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Figure 4.3 Influence of HER2 overexpression or amplification on 5 year mortality in  
patients with oesophageal adenocarcinoma 
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Figure 4.4 Influence of HER2 overexpression or amplification on 5 year mortality in 
patients with oesophageal squamous cell carcinoma 
 
 
4.5 DISCUSSION 
This study represents the largest and only specific meta-analysis of the 
prognostic significance of HER2 overexpression and gene amplification in 
patients with oesophageal carcinoma, all of whom had undergone potentially 
curative oesophagectomy. The main findings from the 14 studies identified were 
that 5 year mortality in patients diagnosed with HER2 positive oesophageal 
cancer were significantly higher compared with patients diagnosed with HER2 
negative cancer. This difference was greater in patients with oesophageal 
squamous cell carcinoma when compared to adenocarcinoma and when 
oesophagogastric junctional cancers were excluded. 
 
The authors searched extensively for relevant studies but most were small and 
inadequately powered on an individual basis to show a significant difference in 
outcomes between patients with HER2 positive and negative oesophageal 
cancer. Only published studies were included as unpublished data from 
conference abstracts lack rigorous peer review. Five of the fourteen studies were 
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ostensibly about other prognostic variables such as p53 (Duhaylongsod et al. 
1995; Hardwick et al. 1997), epidermal growth factor receptor (Friess et al. 1999), 
DNA ploidy (Nakamura et al. 1994) and the Lauren classification (Polkowski et al. 
1999). Two studies investigated the correlation between HER2 status at the 
primary tumour site and metastatic deposits (Reichelt et al. 2007; Stoecklein et 
al. 2008). Including such studies reduced concern about publication bias as the 
decision to publish was unrelated to HER2 status and outcome.  
 
Meta-analysis of retrospective cohort studies is regrettably sensitive to 
confounding. In cancer studies, multiple factors influence prognosis following 
surgery such as age, stage of disease, surgical technique and use of 
neoadjuvant chemotherapy or chemoradiotherapy. To try and account for this, 
only three studies adjusted for two or more of these variables during analysis 
(Nakamura et al. 1994; Polkowski et al. 1999; Langer et al. 2011). This may lead 
to bias which was difficult to assess thoroughly as funnel plots including less than 
ten studies are difficult to interpret. Meta-regression was not performed for the 
same reason (Higgins JPT 2009), but study quality was high in seven of the 
included studies (Nakamura et al. 1994; Polkowski et al. 1999; Brien et al. 2000; 
Stoecklein et al. 2008; Hu et al. 2011; Langer et al. 2011; Thompson et al. 2011). 
Six studies included in this analysis involved more than 100 patients (Hardwick et 
al. 1997; Reichelt et al. 2007; Stoecklein et al. 2008; Sato-Kuwabara et al. 2009; 
Hu et al. 2011; Langer et al. 2011), and use of these latter studies for sensitivity 
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analyses decreased heterogeneity and reinforced significant analyses, making 
the results valid and informative. 
 
The study period spanned 17 years, and hence various laboratory assays were 
used to determine HER2 protein expression and gene amplification. Different 
criteria were also used to define HER2 positivity. Before 2000, all studies used 
IHC to measure the protein overexpressed by the HER2 gene. ISH techniques 
are used to measure gene amplification that rely on either fluorescence (FISH) or 
in more recent studies, chromogenic (Hu et al. 2011) and silver (Thompson et al. 
2011) in-situ hybridization (CISH and SISH). These differences in methodology 
can be seen from the wide range of HER2 positivity in this study (9 to 64%). 
Standardization of IHC and ISH testing is therefore essential. A HER2 scoring 
system for gastric cancer used in the ToGA trial was validated and a 
concordance of 93.5% between FISH and IHC was demonstrated (Hofmann et al. 
2008). However, such a system does not exist for oesophageal cancer and 
whether a separate score should be implemented remains uncertain. 
Nevertheless, most of the studies in this review did not use this validated scoring 
system but various subjective scoring without standardization. Despite these 
differences, results from subgroup analysis related to specific methodology (IHC 
or ISH) were similar to the overall analysis (results not shown). 
 
Subgroup analysis according to histological type showed that HER2 
overexpression and amplification had a greater influence on prognosis in patients 
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with squamous cell carcinoma when compared with adenocarcinoma. It has been 
suggested that this poorer survival in HER2 positive patients with squamous cell 
carcinoma could be due to increased resistance to radiation therapy (Dreilich et 
al. 2006) and cisplatinum-based chemotherapy (Akamatsu et al. 2003). 
Moreover, the addition of trastuzumab in head and neck squamous cell 
carcinoma cell lines seemed to enhance the effect of irradiation (Uno et al. 2001). 
However, as only three studies were included in the analysis of patients with 
squamous cell carcinoma (Hardwick et al. 1997; Friess et al. 1999; Stoecklein et 
al. 2008), these data must be interpreted with caution.   
 
Trastuzumab in combination with standard chemotherapy has been shown to 
improve survival in patients with advanced gastric cancer (Bang et al. 2010) but 
the benefit of neoadjuvant trastuzumab prior to surgery in patients with operable 
oesophageal cancer remains unknown. A randomised controlled trial to address 
this potentially beneficial therapeutic option is warranted. However, recruiting 
sufficient numbers of patients for this trial would be challenging. According to the 
results of this study, approximately 500 patients would be needed to detect this 
survival difference. Assuming that 22% of patients are HER2 positive, 2300 
patients with operable oesophageal cancer would therefore have to be screened 
for eligibility. Despite this, a multinational and multicentre trial could overcome 
these recruitment challenges.  
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4.7 CONCLUSION 
In conclusion, these results confirm that HER2 overexpression and gene 
amplification was an indicator of poor prognosis in patients with operable 
oesophageal cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
 
 
 
 
 
Chapter 5 
 
 
 
Relative prognostic value of HER2 expression in  
operable oesophagogastric cancer 
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5.1  SUMMARY 
The aim of this study was to determine the prognostic significance of HER2 
receptor expression in operable oesophagogastric adenocarcinoma. Eighty-five 
consecutive patients diagnosed with oesophagogastric adenocarcinoma [18 
oesophageal (OC), 32 junctional (JC) and 35 gastric (GC)] undergoing potentially 
curative resection were studied retrospectively. Immunohistochemistry was used 
to determine HER2 status at endoscopic biopsy and resection specimen. The 
primary outcome measure was survival.  
 
Twenty (24%) patients had HER2 positive tumours which was commoner in JC 
(14/32, 44% versus 2/18, 11% in OC and 4/35, 11% in GC, p=0.003). The 
sensitivity, specificity, positive and negative predictive values of HER2 status at 
endoscopic biopsy were 56%, 93%, 63%, 91% respectively (weighted 
Kappa=0.504, p<0.0001). Five year survival in OC HER2 positive vs. HER2 
negative was 100% and 36% (p=0.167) compared with 14% and 44% (p=0.0726) 
in JC and 50% and 46% (p=0.942) in GC respectively.  
 
Endoscopic biopsy had a high specificity and negative predictive value in 
determining HER2 status. Patients with JC had a significantly higher rate of 
HER2 overexpression and this was associated with a nonsignificant poorer 
survival trend. A larger study is needed to confirm these findings because of the 
implications for neoadjuvant and adjuvant chemotherapy regimens. 
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5.2  INTRODUCTION 
The worldwide burden of oesophagogastric cancer is growing. Each year 
482,300 and 989,600 people are diagnosed with oesophageal and gastric cancer 
resulting in 406,000 and 738,00 deaths respectively (Jemal et al. 2011). The 
optimal contemporary treatment is controversial and opinion divided. In 
oesophageal cancer, following the publication of the MRC OEO2 trial, 
neoadjuvant chemotherapy followed by surgery is the standard of care for 
patients with operable oesophageal cancer (MRC Oesophageal Cancer Working 
Group 2002) in the United Kingdom, whereas neoadjuvant chemoradiotherapy 
followed by surgery is the preferred modality in Europe and the United States 
(Ilson 2008). Moreover, the optimum treatment for patients diagnosed with gastric 
cancer in the UK remains controversial, both in terms of neoadjuvant 
chemotherapy (Cunningham et al. 2006) and the extent of the lymphadenectomy.  
However, overall survival reports remain poor and no established global standard 
for treatment exists. New therapies which target specific genetic alterations 
arguably offer the best chance for improving patient survival. 
 
The human epidermal growth factor receptor 2  (HER2) gene is a proto-oncogene 
which is located on chromosome 17q11.2-12 and encodes a transmembrane 
tyrosine kinase receptor which is responsible for cell growth, differentiation, 
migration and apoptosis (Normanno et al. 2005). HER2 is involved in the 
development of numerous types of cancer and is overexpressed in up to 25% of 
breast cancer patients, conferring a poor prognosis (Slamon et al. 1987).  In 
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oesophagogastric cancer, HER2 overexpression has been reported at 
frequencies similar to those observed in breast cancer, ranging from 16% to 27% 
(Polkowski et al. 1999; Tanner et al. 2005; Park et al. 2006; Thompson et al. 
2011).  
 
A combination of the monoclonal antibody against HER2 (trastuzumab) with 
standard chemotherapy improved survival significantly in patients with HER2 
positive advanced gastric cancer in the Trastuzumab for Gastric Cancer (ToGA) 
trial (Bang et al. 2010). All patients in this trial had inoperable junctional or gastric 
adenocarcinoma and there is currently no evidence for the use of trastuzumab in 
operable HER2 positive oesophagogastric cancer in the neoadjuvant setting prior 
to surgery.  
 
The relationship between HER2 overexpression and prognosis  in operable 
oesopahgogastric cancer is controversial (Brien et al. 2000; Reichelt et al. 2007). 
Some studies have suggested that HER2 overexpression is associated with poor 
survival in oesophageal (Flejou et al. 1994; Langer et al. 2011) and gastric 
cancer (Tanner et al. 2005; Park et al. 2006) whereas others have shown no 
association with prognosis (Hardwick et al. 1997; Barros-Silva et al. 2009; 
Grabsch et al. 2010; Hu et al. 2011; Thompson et al. 2011). 
 
The primary aim of this study was therefore to determine the prognostic 
significance of HER2 overexpression in patients with operable oesophagogastric 
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adenocarcinoma. The secondary aim was to determine the accuracy of the 
endoscopic index biopsy in assessing HER2 overexpression when compared 
with the final operative resection specimen. 
 
5.3  METHODS 
Eighty-five consecutive patients diagnosed with oesophagogastric 
adenocarcinoma [18 oesophageal (OC), 32 junctional (JC) and 35 gastric (GC] 
undergoing R0 resection between 1 February 2001 and 30 June 2006 were 
studied retrospectively. All tumours were staged in accordance with the 
International Union against Cancer tumour node metastasis (TNM) classification 
of malignant tumours TNM6 (Sobin et al. 2003). The primary outcome measure 
was survival from diagnosis. Ethical approval was obtained from the local ethics 
committee. 
 
5.3.1  Neoadjuvant chemotherapy 
The selective use of neoadjuvant chemotherapy was adopted in the latter part of 
the study period and was given to 25 patients with minimal comorbidities who 
were deemed to have relatively advanced disease and would benefit from down-
staging of the tumour prior to surgery. Chemotherapy was administered for three 
or four cycles preoperatively and postoperatively. Each cycle consisted of 
epirubicin (50mg/ m2) by intravenous bolus, cisplatin (60mg/ m2) as a four-hour 
infusion on day one and 5-fluorouracil (200mg/ m2/day) daily by a continuous 
intravenous infusion. 
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5.3.2  Surgical treatment 
Patients with oesophageal cancer were selected for radical treatment based on 
perceived radiologic stage, comorbidity and patient choice according to 
algorithms described previously (Crosby et al. 2004; Stephens et al. 2006; 
Gwynne et al. 2011). The type of surgery for gastric cancer was determined by 
the anatomical location of the tumour; subtotal gastrectomy was performed in 
patients with antral tumours and total gastrectomy was performed in tumours of 
the cardia (Siewert type III), body and linitis plastica. A modified D2 
lymphadenectomy preserving the spleen and pancreas was performed (Edwards 
et al. 2004). 
 
5.3.3  Immunohistochemistry 
Immunohistochemistry (IHC) was used to determine patients’ HER2 status at the 
endoscopic index biopsy and the final operative resection specimen. Sections 
(4µm) of tissue were cut, mounted on coated slides, labeled and then placed on 
the Ventana Benchmark XT (Roche Diagnostics) for detection of the HER2 
oncoprotein. The sections were dewaxed then subjected to pretreatment with 
CC1 for 30 minutes. Sections were then washed with reaction buffer followed by 
incubation with the rabbit monoclonal primary antibody HER2/neu (Clone 4B5, 
PATHWAY) for 16 minutes. On board detection using ultraView Universal DAB kit 
(Roche Diagnostics), used in accordance with the manufacturer’s 
recommendations, was used to detect the location of the primary antibody HER2 
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followed by counterstain with haematoxylin II for four minutes (Roche 
Diagnostics). 
 
All sections were reviewed independently by two consultant histopathologists 
who were blinded to all clinical and pathological information. Discordant cases 
were reviewed together and a final consensus was reached. Evaluation and 
scoring of HER2 protein overexpression was performed according to the Dako 
HercepTest scoring system for breast cancer. Only membranous staining was 
considered. This scoring system has been validated for use in gastric cancer with 
minimal modifications: 0/negative = staining or membranous reactivity in <10% of 
cells; 1+/negative = faint membranous reactivity in >10% of cells or cells with 
reactivity only in part of their membrane; 2+/equivocal = weak/moderate complete 
or basolateral membranous staining in >10% of tumour cells; and 3+/positive = 
strong complete or basolateral membranous staining in >10% of tumour cells 
(Hofmann et al. 2008; Walker et al. 2008).  
 
5.3.4 Follow-up evaluation 
Patients were reviewed every three months for the first year, then every six 
months thereafter. The median follow-up period was 71 months. A total of 79 
patients (93%) were followed up for at least five years or until death. Death 
certification was obtained from the Office for National Statistics.  
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5.3.5 Statistical analysis 
Statistical analysis appropriate for non-parametric data was used. Grouped data 
were expressed as median (range). Groups were compared with the Mann-
Whitney U test for unpaired data. The agreement between HER2 status at index 
biopsy and the postoperative histopathological resection specimen was 
determined using the weighted Kappa statistic (Kw) (Landis et al. 1977). The 
value of Kappa has a maximum of 1.00 when agreement is perfect, a value of 
zero indicates no agreement better than chance and negative values show worse 
than chance agreement. The strength of agreement was assessed according to 
the guidelines of Landis and Koch (Landis et al. 1977). The sensitivity and 
specificity, positive predictive value and negative predictive value were also 
estimated. Cumulative survival was calculated by the life table method of Kaplan 
and Meier (Kaplan et al. 1958). Differences in survival times between groups of 
patients were analysed by the log rank method (Altman 1991). Multivariate Cox 
regression was used to assess the prognostic value of individual variables. Data 
analysis was carried out with the Statistical Package for Social Sciences (SPSS) 
version 18 (SPSS, Chicago, Illinois, USA). 
 
5.4 RESULTS 
Twenty (24%) patients had HER2 positive tumours, and positive HER2 status 
was commoner in JC (14/32, 44% versus 2/18, 11% in OC and 4/35, 11% in GC; 
Chi2 = 11.66, p=0.003), Table 5.1.  
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5.4.1 Accuracy of biopsy in determining HER2 status 
Comparison of HER2 expression status between the index biopsy and final 
operative resection specimen revealed sensitivity, specificity, positive and 
negative predictive values were 56%, 93%, 63%, 91% respectively. There was 
strong agreement between the index biopsy and final operative resection 
specimen [weighted Kappa statistic was 0.504; 95% CI 0.128 - 0.856; p<0.0001)]. 
Only three patients had a false positive biopsy result, all of whom had undergone 
gastrectomy without neoadjuvant chemotherapy. 
 
5.4.2 Outcomes related to HER2 expression 
Short-term outcomes were similar in patients with HER2 positive and negative 
tumours (Table 5.2). Cumulative five year survival related to HER2 status was 
30% for the HER2 positive cohort compared with 43% for the HER2 negative 
cohort (p=0.221), (Figure 5.1). With regard to tumour site, five year survival in OC 
HER2 positive versus negative cohorts was 100% and 36% (p=0.167) compared 
with 14% and 44% (p=0.0726) in JC (Figure 5.2) and 50% and 46% (p=0.942) in 
GC respectively. Univariate analysis of factors associated with duration of 
survival is shown in Table 5.3. 
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Table 5.1  Details of patients 
   OC  JC  GC  p value 
Number  18  32  35 
Median age (years) 60  66  72  0.012 
Gender M:F (%) 18:0 (100:0) 27:5 (84:16) 19:16 (54:46) <0.0001 
Surgery (%) TTO 7 (39)  9 (28)  - 
  THO 11 (61) 13 (41) - 
TG -  10 (31) 9 (26) 
  STG -  -  26 (74) 
HER2+ (%) 2 (11)   14 (44) 4 (11)  0.003 
pTNM (%) I&II 10 (56) 12 (37) 20 (57) 0.062 
  III&IV 8 (44)  20 (63) 15 (43) 
 
OC: Oesophageal adenocarcinoma; JC: Junctional adenocarcinoma; GC: Gastric 
adenocarcinoma; TTO: Transthoracic oesophagectomy; THO: Transhiatal 
oesophagectomy; TG: Total gastrectomy; STG: Subtotal gastrectomy 
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Table 5.2  Outcome related to HER2 overexpression 
 
    HER2 -  HER2 + p value 
Number (%)   65 (76)  20 (24) 
Median age (years)  66   69  0.705 
Gender M:F (%)  48:17 (74:26) 16:4 (80:20) 0.577 
pTNM (%) I & II  (52)   (40)  0.089  
  III & IV (48)   (60) 
Morbidity (%)   23 (35)  7 (35)  0.975  
Mortality (%)   2 (3)   1 (5)  0.47 
Median survival (months) 43   27  0.221 
1 year survival (%)  89   80 
2 year survival (%)  61   55 
5 year survival (%)  43   30 
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Table 5.3  Univariate analysis of factors associated with duration of survival 
Factor   Chi2  df p value 
HER2 overexpression 1.497  1 0.221  
pT stage   17.346 3 0.001 
Age    68.826 4 0.001  
pN stage   34.272 3 <0.0001 
pTNM stage   30.786 3 <0.0001 
Lymph node ratio  183.926 3 <0.0001 
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Figure 5.1  Survival related to HER2 overexpression in all patients 
 
 
Caption 
Numbers at risk 
HER2 -    65  56      39  35      29  21  
HER2 +   20  16      11  8      7  5  
 
— =  HER2 +   ----- = HER2 -   
Log rank = 1.497, df. 1 (p=0.221)  
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Figure 6.2  Survival related to HER2 overexpression in patients with junctional 
adenocarcinoma 
 
Caption 
Numbers at risk 
HER2 -    18  16      11  9      8  4  
HER2 +   14  10      7  4      4  2  
— =  HER2 +   ----- = HER2 -   
Log rank = 3.233, df. 1, p=0.072  
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5.5  DISCUSSION 
HER2 overexpression was found in 24% of patients in this cohort, the majority of 
whom had tumours situated around the oesophagogastric junction. This is in 
keeping with recent studies reporting a prevalence rate of 15 to 30% (Bang et al. 
2010; Langer et al. 2011; Thompson et al. 2011). The previously quoted range of 
11 to 73% largely originates from studies conducted in the 1990s which adopted 
various cutoffs for the classification of HER2 status preventing valid comparisons 
to be made (Flejou et al. 1994; Nakamura et al. 1994; Duhaylongsod et al. 1995; 
Friess et al. 1999). There was a trend towards poorer long-term survival in 
patients diagnosed with HER2 positive operable oesophagogastric cancer 
compared to patients with HER2 negative tumours. However, this difference was 
not statistically significant and this finding echoes more recent reports which have 
also shown that HER2 overexpression was not associated with duration of 
survival (Reichelt et al. 2007; Stoecklein et al. 2008; Hu et al. 2011; Thompson et 
al. 2011).    
 
The accuracy of endoscopic biopsy in determining HER2 status in 
oesophagogastric cancer has not been documented previously. We report a high 
specificity and negative predictive value of endoscopic biopsy in determining 
HER2 status in oesophagogastric cancer. However, the sensitivity and positive 
predictive value was lower when compared with breast core-needle biopsies 
(Arnould et al. 2012). The pattern of HER2 staining in breast cancer tends to be 
homogenous whereas HER2 staining in gastric cancer is heterogeneous 
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(Hofmann et al. 2008). A modified scoring system which only takes into account 
the pattern of reactivity irrespective of the number of reactive cells in biopsy 
specimens has therefore been introduced (Hofmann et al. 2008). 
 
This study has several potential limitations. This was a retrospective 
observational study and is therefore open to selection bias. The relatively small 
sample size could have resulted in a type II error. HER2 status was determined 
using IHC on tissue samples which have been stored for a few years prior to 
analysis. Deterioration in antigenicity can occur once sections from paraffin 
blocks have been put onto slides (Jacobs et al. 1996) and could arguably 
underestimate the prevalence of HER2 overexpression in our cohort.  However, 
this appears to be a limitation of most studies published on this subject (Hardwick 
et al. 1997; Akamatsu et al. 2003; Thompson et al. 2011). Although the 
assessment of HER2 gene amplification with in-situ hybridisation (ISH) 
techniques has been recommended to determine the final HER2 status in 
equivocal IHC 2+ (Hofmann et al. 2008),  we did not perform ISH on the five 
patients in our cohort who had IHC 2+ as the concordance between IHC and ISH 
have been shown to be high (Dowsett et al. 2003; Hofmann et al. 2008). 
 
Conversely, the strengths of the study are that the demographic data and 
outcomes were collected prospectively, from a well-defined geographical area 
served by an established regional upper GI network. The study’s survival and 
prognostic data are especially robust because no patients were lost to follow-up, 
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and causes and exact dates of death were obtained from death certificates 
provided by the Office for National Statistics. HER2 status was determined by two 
specialist consultant histopathologists, one of whom was part of the steering 
group recommending guidelines for HER2 testing in the UK (Ellis et al. 2004; 
Walker et al. 2008; Bartlett et al. 2011).  
 
A larger prospective study using validated and reproducible methods in IHC and 
ISH is needed to clarify the prognostic role of HER2 in patients with operable 
oesophagogastric cancer. The accuracy of the index biopsy at determining HER2 
status is important as the addition of anti-HER2 therapy to the standard 
neoadjuvant chemotherapy regime may be beneficial in HER2 positive patients. 
Future studies into targeted molecular therapies should also take into account 
characteristics of both the primary tumour and disseminated tumour cells 
(Thompson et al. 2011). 
 
5.5  CONCLUSION 
Endoscopic biopsy had a high specificity and negative predictive value in 
determining HER2 status. Patients with JC had a significantly higher rate of 
HER2 overexpression and this was associated with a nonsignificant poorer 
survival trend. A larger study is needed to confirm these findings because of the 
implications for neoadjuvant and adjuvant chemotherapy regimens. 
. 
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Chapter 6 
 
 
 
Systematic review and meta-analysis of the influence of 
circumferential resection margin involvement on survival in patients with 
operable oesophageal cancer 
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6.1 SUMMARY  
The prognostic role and definition of circumferential resection margin (CRM) 
involvement in operable oesophageal cancer remains controversial. The College 
of American Pathologists (CAP) and Royal College of Pathologists (RCP) define 
CRM involvement as tumour found at the cut resection margin and within 1 mm 
of the cut resection margin respectively. This systematic review and meta-
analysis was performed to determine the influence of CRM involvement on 
outcomes in operable oesophageal cancer. 
 
PubMed, MEDLINE and the Cochrane Library (January 1990 to June 2012) were 
searched for studies correlating CRM involvement with five year mortality. 
Statistical analysis of dichotomous variables was performed using odds ratio 
(OR) as the summary statistic. 
 
Fourteen studies involving 2433 patients with oesophageal cancer who had 
undergone potentially curative oesophagectomy were analysed. Rates of CRM 
involvement were 15.3% (173/1133) and 36.5% (889/2433) according to the CAP 
and RCP criteria respectively. Overall five year mortality rates were significantly 
higher in patients with CRM involvement compared with CRM-negative patients 
according to the CAP [OR 4.02, 95% confidence interval (CI) 2.25-7.20, 
p<0.00001] and RCP (OR 2.52, 95% CI 1.96-3.25, p<0.0001) criteria. CRM 
involvement between 0.1 to 1 mm was associated with significantly higher five 
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year mortality than CRM negative status (involvement more than 1 mm from 
CRM) [OR 2.05, 95% CI 1.41-2.99, p<0.00001]. 
 
CRM involvement is an important predictor of poor prognosis. CAP criteria 
differentiate a higher risk group than RCP criteria, but overlook a patient group 
with similar poor outcomes.  
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6.2 INTRODUCTION 
Although prognosis after oesophageal cancer resection has improved over the 
last decade, long-term survival remains poor (Khan et al. 2010; Cancer Research 
UK 2012). Traditionally, the depth of tumour invasion and the number of lymph 
node metastases have been the most important prognostic indicators following 
curative oesophagectomy (Shahbaz Sarwar et al. 2010) but more recently 
increasing interest has developed in the prognostic value of circumferential 
resection margin (CRM) involvement.  
 
Although CRM involvement is a well established independent prognostic indicator 
in patients with rectal cancer (Adam et al. 1994; Birbeck et al. 2002), reports on 
its role in oesophageal cancer have been conflicting (Dexter et al. 2001; Khan et 
al. 2003; Deeter et al. 2009; Harvin et al. 2012). The two largest series of over 
300 patients have each reported that CRM involvement was not an independent 
predictor of prognosis (Khan et al. 2003; Mirnezami et al. 2010), in contrast to 
smaller studies (Dexter et al. 2001; Griffiths et al. 2006; Deeter et al. 2009). 
 
On the basis of evidence available at the time suggesting that CRM involvement 
resulted in higher rates of local recurrence and poorer survival (Sagar et al. 
1993), the UK Royal College of Pathologists (RCP) included CRM status as a 
required data item in the 1998 minimum dataset for oesophageal cancer 
(Mapstone 1998; Mapstone 2006). The RCP defined CRM involvement as 
tumour involvement within 1 mm of the cut margin, whereas the College of 
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American Pathologists (CAP) considered CRM involvement as tumour found at 
the cut margin of resection (Pathologists 2005). The optimum definition for CRM 
involvement in predicting outcome remains uncertain and several studies have 
supported either the RCP (Scheepers et al. 2009; Pultrum et al. 2010; Salih et al. 
2013) or CAP (Deeter et al. 2009; Verhage et al. 2011) classification. 
 
The aim of this study was to perform a systematic review and meta-analysis of 
the influence of CRM involvement on overall survival in patients with operable 
oesophageal cancer. Secondary aims included determining the optimum 
definition of CRM involvement and the prognostic significance of CRM 
involvement in patients with T3 tumours with and without nodal involvement and 
those undergoing neoadjuvant therapy before surgery. 
 
6.3  METHODS 
6.3.1 Literature Search Strategy 
A systematic review of published work was conducted according to the Preferred 
Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines 
(Moher et al. 2009). A systematic search of PubMed, MEDLINE and the 
Cochrane Library databases was performed from January 1990 to June 2012 
using the following terms to identify studies investigating the influence of CRM 
involvement on survival in patients with operable oesophageal cancer: 
oesophageal neoplasm, oesophagectomy, surgery, circumferential resection 
margin, outcomes and survival. The searches were limited to human articles 
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published in the English language. Further articles were identified by hand 
searching reference lists of all articles retrieved to identify potentially relevant 
studies. Searches were cross-referenced on PubMed using the related articles 
function. The last search date was 30 June 2012.  
 
6.3.2 Data extraction 
Data were extracted independently by three authors using a standard protocol. 
Any discrepancies were dealt with by discussion among all authors and a 
consensus was reached. The following information was extracted from each 
study: first author, year of publication, study design, country of origin, definition of 
CRM involvment used, number of subjects with CRM involvement, histological 
subtype (adenocarcinoma or squamous cell carcinoma), use of neoadjuvant 
chemotherapy and or chemoradiotherapy, mean follow-up, quality of study and 
outcome measures (all-cause mortality). Sub-group analysis was performed 
according to classification of CRM involvement, T3 tumours and use of 
neoadjuvant chemotheray or chemoradiotherapy. 
 
6.3.3 Inclusion and exclusion criteria 
Studies comparing overall survival outcomes in patients with operable 
oesophageal cancer with and without CRM involvement were included. Where 
there were multiple articles by the same authors analysing data from the same or 
a similar patient group, the most recent publication was included if the study 
periods overlapped. Review articles, case reports, experimental studies and 
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studies that did not report outcomes were excluded. Unpublished data from 
conference abstracts were excluded. Only high-quality studies with more than 
100 patients were included. 
 
6.3.4 Statistical analysis 
The meta-analysis was performed in line with the recommendations from the 
Cochrane Collaboration and PRISMA guidelines (Moher et al. 2009) using 
Review Manager 5.1 (The Nordic Cochrane Centre, The Cochrane Collaboration, 
Copenhagen, Denmark). Statistical analysis of dichotomous variables were 
carried out using odds ratio (OR) as the summary statistic. The decision to use a 
fixed-effects model was made in advance as minimal heterogeneity was 
expected. The pooled ORs were reported with 95% confidence intervals (CI). 
ORs represent the odds of death during the study interval in a patient who was 
CRM-positive compared with a patient who was CRM-negative. An OR of greater 
than 1 indicated a higher mortality rate in patients who had CRM involvement, 
and the point estimate of the OR was considered significant at the p<0.050 level 
if the 95% CI did not include 1.  
 
The quality of non-randomised studies was assessed using the Newcastle-
Ottawa scale (Higgins JPT 2009) which examines patient selection methods, 
comparability of study groups and assessment of outcome. A score of at least 
seven stars from a maximum of nine were considered to be of higher quality. 
Heterogeneity was assessed using the I2 value which was reported for each 
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analysis. Funnel plots were used to assess publication bias (Egger et al. 1998). 
Funnel plot asymmetry implied that results were subject to reporting or 
publication bias. 
 
6.4 RESULTS 
The full text of 30 papers were obtained, of which 14 cohort studies fulfilled the 
criteria for review (Figure 6.1). Analysis was carried out on 2433 patients (1884 
male; median age 64 years) with oesophageal carcinoma (adenocarcinoma, 
1789; squamous cell carcinoma, 623; other histology, 21), all of whom had 
undergone attempted curative oesophagectomy (transthoracic, 1929; transhiatal, 
277; three-stage, 124; laparoscopically assisted, 103).  
 
6.4.1 Characteristics of included studies (Table 6.1) 
All studies analysed were observational cohort, of which two had a prospective 
design (Dexter et al. 2001; Deeter et al. 2009). Of the 14 studies, 13 (Dexter et al. 
2001; Khan et al. 2003; Griffiths et al. 2006; Sujendran et al. 2008; Deeter et al. 
2009; Saha et al. 2009; Scheepers et al. 2009; Pultrum et al. 2010; Chao et al. 
2011; Verhage et al. 2011; Harvin et al. 2012; Rao et al. 2012; Salih et al. 2013) 
reported three year and ten (Khan et al. 2003; Griffiths et al. 2006; Thompson et 
al. 2008; Deeter et al. 2009; Scheepers et al. 2009; Pultrum et al. 2010; Chao et 
al. 2011; Verhage et al. 2011; Harvin et al. 2012; Rao et al. 2012) reported five 
year mortality outcomes. Only two studies reported local recurrence rates (Chao 
et al. 2011; Harvin et al. 2012). The RCP classification was used in all studies to 
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define CRM involvement. Eight studies used both the RCP and CAP 
classifications (Deeter et al. 2009; Scheepers et al. 2009; Pultrum et al. 2010; 
Chao et al. 2011; Verhage et al. 2011; Harvin et al. 2012; Rao et al. 2012; Salih 
et al. 2013). Nine studies reported CRM involvement to be a significant predictor 
of poor prognosis in univariable (Chao et al. 2011) and multivariable analysis 
(Dexter et al. 2001; Griffiths et al. 2006; Sujendran et al. 2008; Deeter et al. 2009; 
Saha et al. 2009; Scheepers et al. 2009; Pultrum et al. 2010; Verhage et al. 
2011). In six studies, the significance of CRM involvement was negated by other 
factors such as the number of lymph node metastases (Khan et al. 2003; 
Thompson et al. 2008; Harvin et al. 2012; Rao et al. 2012; Salih et al. 2013), T 
stage (Khan et al. 2003), lymphovascular invasion (Mirnezami et al. 2010) and 
tumour grade (Thompson et al. 2008; Mirnezami et al. 2010).  
 
6.4.2 Characteristics of excluded studies 
Four studies were excluded from analysis (Sagar et al. 1993; Roh et al. 2004; 
Barbour et al. 2007; Sillah et al. 2009). Two studies had small sample sizes (less 
than 100) with short durations of follow-up and Newcastle-Ottawa scores of less 
than 7 (Sagar et al. 1993; Roh et al. 2004). Although CRM involvement was 
reported in these two studies as a predictor of poor prognosis, other factors were 
not corrected for in multivariable analysis. Two other studies examined the 
influence of other factors such as the degree of involvement of oesophageal 
circumference (Sillah et al. 2009) and longitudinal resection margins (Barbour et 
al. 2007). 
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6.4.3 Method of examining CRM involvement 
In 11 studies (Dexter et al. 2001; Khan et al. 2003; Griffiths et al. 2006; Sujendran 
et al. 2008; Deeter et al. 2009; Saha et al. 2009; Scheepers et al. 2009; Pultrum 
et al. 2010; Chao et al. 2011; Verhage et al. 2011; Salih et al. 2013), the 
specimen was delivered fresh and unopened to the pathology department with no 
dissection of lymph nodes. Specimens were then painted with Indian ink to allow 
better microscopic assessment followed by fixation in formalin for 24 to 48 hours. 
Specimens were then cut to between 3 and 5 mm in thickness and assessed by 
one to three consultant histopathologists for CRM involvement according to the 
RCP and CAP criteria. Three studies did not detail the method of specimen 
preparation prior to assessment of CRM involvement (Thompson et al. 2008; 
Harvin et al. 2012; Rao et al. 2012). In 12 studies, the specimens were reviewed 
by either a single specialist pathologist (Thompson et al. 2008; Deeter et al. 
2009; Saha et al. 2009; Chao et al. 2011; Verhage et al. 2011; Harvin et al. 2012) 
or a team of up to three pathologists (Khan et al. 2003; Griffiths et al. 2006; 
Sujendran et al. 2008; Scheepers et al. 2009; Rao et al. 2012; Salih et al. 2013).  
 
6.4.4 CRM involvement in all patients 
The rates of CRM involvement were 15.3% (173/1133) and 36.5% (889/2433) 
according to the CAP and RCP criteria respectively. Overall three year mortality 
was significantly higher in patients with CRM involvement compared with CRM-
negative patients according to the CAP (OR 3.13, 95% CI 2.12-4.63, p<0.00001) 
and RCP (OR 2.49, 95% CI 2.02-3.06, p<0.0001) criteria (Table 6.2). Overall five 
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year mortality rates were also significantly higher in patients with CRM 
involvement compared with CRM-negative patients according to the CAP [OR 
4.02, 95% CI 2.25-7.20, p<0.00001] and RCP (OR 2.52, 95% CI. 1.96-3.25, 
p<0.0001) criteria (Table 6.3, Figures 6.2 and 6.3). The CAP criteria resulted in 
larger ORs than the RCP criteria. 
 
6.4.5 CRM involvement in patients with T3 tumours 
Overall, ten studies reported separate outcomes for patients with T3 tumours 
(Khan et al. 2003; Griffiths et al. 2006; Sujendran et al. 2008; Deeter et al. 2009; 
Saha et al. 2009; Scheepers et al. 2009; Chao et al. 2011; Verhage et al. 2011; 
Rao et al. 2012). The rate of CRM involvement was 14.6% (110/754) and 42.5% 
(597/1405) according to the CAP and RCP criteria respectively.  
 
Of the ten studies, three (Griffiths et al. 2006; Sujendran et al. 2008; Scheepers 
et al. 2009) reported separate outcomes according to node status using the RCP 
criteria. Positive node status negated the importance of CRM involvement in the 
three year mortality analysis but not the five year mortality analysis (Tables 6.2 
and 6.3).  
 
6.4.6 CRM involvement in patients undergoing surgery alone 
Five studies reported separate outcomes for patients who had undergone surgery 
alone (Dexter et al. 2001; Khan et al. 2003; Thompson et al. 2008; Pultrum et al. 
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2010; Verhage et al. 2011). The rate of CRM involvement was 22.2% (51/230) 
and 40.1% (325/810) according to the CAP and RCP criteria respectively. 
 
6.4.7 CRM involvement in patients undergoing neoadjuvant chemotherapy 
Six studies (Griffiths et al. 2006; Sujendran et al. 2008; Saha et al. 2009; 
Scheepers et al. 2009; Rao et al. 2012; Salih et al. 2013) included  patients who 
had undergone neoadjuvant CT prior to surgery according to the MRC OEO2 
regimen (Medical Research Council Oesophageal Cancer Working Group 2002). 
The rate of CRM involvement was 15.8% (72/457) and 34.3% (361/1053) 
according to the CAP and RCP criteria respectively.  
 
6.4.8 CRM involvement in patients undergoing neoadjuvant chemo-
radiotherapy  
Five studies included patients who had undergone neoadjuvant 
chemoradiotherapy prior to surgery (Sujendran et al. 2008; Thompson et al. 
2008; Deeter et al. 2009; Chao et al. 2011; Harvin et al. 2012), one of which did 
not report combined outcomes (Thompson et al. 2008). One study only included 
nine patients who had undergone neoadjuvant CRT and was therefore excluded 
from the analysis (Sujendran et al. 2008). The rate of CRM involvement was 
11.2% (50/446) and 31.9% (259/812) according to the CAP and RCP criteria 
respectively.  
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6.4.9 Local recurrence related to CRM involvement 
Two studies reported local recurrence outcome (Chao et al. 2011; Harvin et al. 
2012) and both only included patients with T3 tumours who had undergone 
neoadjuvant CRT. The local recurrence rate was 35.3% (12/34) in patients with 
CRM involvement and 16.2% (45/277) in patients without CRM involvement 
according to the CAP criteria (OR 1.90 95% CI 0.84-4.28, p=0.12, I2=0%). 
According to the RCP criteria, the local recurrence rate was 28.6% (34/119) in 
patients with CRM involvement and 12.0% (23/192) in patients without CRM 
involvement (OR 2.15 95% CI 1.15-4.01, p=0.02, I2=0%). 
 
6.4.10 Outcome in patients with CRM involvement of 0.1 to 1mm 
Meta-analysis of the eight studies which used both definitions was performed to 
determine the outcome in patients differentiated by the RCP but not the CAP 
criteria (Table 6.4, Figures 6.4 and 6.5). Three and five year mortality was 
significantly higher in this group of patients compared with rates in those with no 
involvement within 1mm of the cut margin (OR 2.15 95% CI 1.59-2.91, p<0.001 
and OR 2.05 95% CI 1.41-2.99, p<0.001 respectively). However, this difference 
in outcome was not significant in patients who had undergone neoadjuvant 
chemoradiotherapy. 
 
6.4.11 Heterogeneity and publication bias 
Statistical heterogeneity was identified in only three analyses using the RCP 
criteria: three and five year mortality in patients who had undergone surgery 
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alone, and five year mortality in all patients. There was no heterogeneity among 
analyses using the CAP criteria. The funnel plots for three and five year mortality 
rates for all patients were symmetrical, indicative of the absence of publication 
bias. 
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Table 6.1 Characteristics of studies included in the meta-analysis 
 
N/A: Not available, CAP: College of American Pathologist (CRM at margin), RCP: 
Royal College of Pathologist (CRM≤1mm), UA – univariable analysis, MA – 
multivariable analysis, NO – Newcastle-Ottawa Study Quality Score, CT – 
Neoadjuvant chemotherapy, CRT – neoadjuvant chemoradiotherapy. In studies 
which used both definitions of CRM involvement, * indicates the definition which 
is more prognostically significant. 
 
 
First author, 
year 
Country CRM 
definition 
Tota
l No. 
CRM 
at 
margin 
(per 
cent) 
CRM 
≤1mm 
(per 
cent) 
No. ≥T3  
(per 
cent) 
Neo-
adjuv
ant 
thera
py 
 
Surviv
al 
related 
to 
CRM+ 
on MA 
Mean 
follow
-up 
(mont
hs) 
NO  
Chao 2011 Taiwan CAP*& RCP 151 26 
(17.2) 
51 
(33.8) 
151 
(100.0) 
CRT No 50.0 7 
Deeter 2009 USA CAP*& RCP 135 16 
(11.9) 
83 
(61.5) 
135 
(100.0) 
CRT Yes  37.2 8 
Dexter 2001 UK RCP 135 N/A 64 
(47.4) 
95 
(70.4) 
None Yes  19.0 8 
Griffiths 
2006 
UK RCP 249 N/A 79 
(31.7) 
145 
(58.2) 
CT Yes  70.0 9 
Harvin 2012 USA CAP*& RCP 160 8 (5.0) 42 
(26.3) 
160 
(100.0) 
CRT No  N/A 7 
Khan 2003 UK RCP 329 N/A 67 
(20.4) 
267 
(81.2) 
None No 60.0 9 
Pultrum 
2010 
Netherlands CAP& RCP* 98 25 
(25.5) 
47 
(48.0) 
58 
(59.2) 
None Yes  37.0 9 
Rao 2012 UK CAP& RCP* 115 17 
(14.8) 
57 
(49.6) 
80 
(69.6) 
CT No  38.0 8 
Saha 2009 UK RCP 105 N/A 38 
(36.2) 
70 
(66.7) 
CT Yes  26.0 8 
Salih 2013 UK CAP& RCP* 232 38 
(16.4) 
89 
(38.4) 
171 
(73.7) 
CT No  18.0 8 
Scheepers 
2009 
Netherlands CAP& RCP* 110 17 
(15.5) 
42 
(38.2) 
86 
(78.2) 
CT Yes  N/A 8 
Sujendran 
2007 
UK RCP 242 N/A  56 
(23.1) 
151 
(62.4) 
CT & 
CRT 
Yes N/A 8 
Thompson 
2008 
Australia RCP 240 N/A 85 
(35.4) 
127 
(52.9) 
CRT No  N/A 8 
Verhage 
2011 
Netherlands CAP*& RCP 132 26 
(19.7) 
89 
(67.4) 
132 
(100.0) 
None Yes  28.4 8 
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Table 6.2  Three year mortality related to CRM involvement according to  
  a) RCP and b) CAP criteria.  
 
a. RCP criteria 
 No. of 
studies 
CRM + CRM - OR (95% CI) p Heteroge-
neity 
  Events Total Events Total   I2 % p 
All  13 607 861 652 1178 2.49 (2.02-3.06) <0.001 38 0.08 
Surgery 4 191 267 247 427 2.11 (1.47-3.03) <0.001 68 0.02 
NCT 6 267 392 257 507 2.88 (2.11-3.92) <0.001 0 0.59 
NCRT 3 149 202 148 244 2.34 (1.51-3.61) 0.001 54 0.12 
T3 9 430 556 364 582 2.35 (1.79-3.10) <0.001 0 0.70 
T3N0 3 55 73 43 82 2.88 (1.43-5.77) 0.003 0 0.55 
T3N1 3 86 97 99 121 1.92 (0.87-4.26) 0.110 0 0.83 
 
b. CAP criteria 
 No. of 
studies 
CRM + CRM - OR (95% CI) p Heteroge-
neity 
  Events Total Events Total   I2 % p 
All 8 128 173 515 960 3.13 (2.12-4.63) <0.001 13 0.33 
Surgery 2 39 51 101 179 3.69 (1.65-8.29) 0.002 0 0.85 
NCT 3 45 72 163 385 2.40 (1.41-4.08) 0.001 60 0.08 
NCRT 3 44 50 251 396 4.51 (1.91-10.7) 0.0006 0 0.84 
T3 6 94 110 420 669 3.83 (2.20-6.69) <0.001 0 0.35 
T3N0 0     N/A    
T3N1 0     N/A    
 
RCP – Royal College of Pathologists; CAP – College of American Pathologists; N 
– number of studies included; OR – Odds ratio; NCT – Neoadjuvant 
chemotherapy; NCRT – Neoadjuvant chemoradiotherapy. 
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Table 6.3  Five year mortality related to CRM involvement according to  
  a) RCP and b) CAP criteria. 
 
a. RCP criteria 
 No. of 
studies 
CRM + CRM - OR (95% CI) p Heterogen-
eity 
  Events Total Events Total   I2 % p 
All  10 541 661 689 1034 2.52 (1.96-3.25) <0.001 50 0.03 
Surgery 4 219 261 263 414 3.08 (2.04-4.66) <0.001 74 0.009 
NCT 3 149 171 183 279 4.06 (2.39-6.89) <0.001 44 0.17 
NCRT 4 185 229 241 341 2.08 (1.34-3.22) 0.001 2 0.38 
T3 8 438 529 492 659 1.94 (1.43-2.63) <0.001 36 0.14 
T3N0 2 50 58 42 60 2.65 (1.03-6.83) 0.040 0 0.49 
T3N1 2 55 56 45 54 7.63 (1.33-40.6) 0.020 60 0.11 
 
b. CAP criteria 
 No. of 
studies 
CRM + CRM - OR (95% CI) P Heterogen-
eity 
  Events Total Events Total   I2 % p 
All  7 121 135 560 766 4.02 (2.25-7.20) <0.001 21 0.27 
Surgery 2 44 51 123 179 4.25 (1.66-10.9) 0.003 0 0.82 
NCT 2 29 34 130 191 2.50 (0.96-6.53) 0.060 73 0.05 
NCRT 3 48 50 307 396 6.34 (1.92-20.9) 0.002 0 0.50 
T3 6 102 110 515 669 3.78 (1.88-7.57) 0.0002 30 0.21 
T3N0 0     N/A    
T3N1 0     N/A    
 
RCP – Royal College of Pathologists; CAP – College of American Pathologists; N 
– number of studies included; OR – Odds ratio; NCT – Neoadjuvant 
chemotherapy; NCRT – Neoadjuvant chemoradiotherapy. 
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Table 6.4 Overall mortality in patients with CRM involvement between  
  0.1 and 1mm 
 
a. Three year mortality 
 No. of 
studies 
CRM 0.1-
1mm 
CRM >1mm OR (95% CI) p Heteroge-
neity 
  Events Total Events Total   I2 % p 
All  8 211 327 265 569 2.15 (1.59-2.91) <0.001 31 0.18 
Surgery 2 62 85 39 94 2.66 (1.36-5.20) 0.004 76 0.04 
NCT 3 66 116 78 231 2.70 (1.68-4.33) <0.001 0 0.66 
NCRT 3 83 126 148 244 1.53 (0.94-2.49) 0.090 0 0.39 
T3 5 159 229 202 345 1.75 (1.19-2.56) 0.004 0 0.44 
T3N0 0     N/A    
T3N1 0     N/A    
 
b. Five year mortality 
 No. of 
studies 
CRM 0.1-
1mm 
CRM >1mm OR (95% CI) p Heterogen-
eity 
  Event
s 
Total Events Total   I2 % p 
All  7 220 276 308 464 2.05 (1.41-2.99) 0.0002 52 0.05 
Surgery 2 73 85 50 94 3.81 (1.72-8.45) 0.001 0 0.42 
NCT 2 54 65 69 126 3.89 (1.85-8.18) 0.0003 0 0.50 
NCRT 3 93 126 189 244 1.03 (0.59-1.79) 0.910 0 0.88 
T3 5 184 229 259 345 1.50 (0.97-2.33) 0.070 22 0.28 
T3N0 0     N/A    
T3N1 0     N/A    
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Figure 6.1 Identification process for eligible studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records after duplicates removed 
(n=709) 
Records screened by abstract 
(n=709) 
Records excluded 
(n=691) 
Full text assessed for eligibility 
(n=30) 
Records excluded 
(n=16) 
16 not meeting inclusion criteria 
 
Studies included in meta-analysis 
(n=14) 
Records identified through 
database searching 
(n=709) 
Records identified through other 
sources 
(n= 18) 
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 Figure 6.2 Influence of CRM involvement on 5 year mortality in all patients  
 with oesophageal carcinoma according to the RCP criteria. Weights are from 
fixed effects analysis. Squares indicate the point estimates of the effect of 
disease (odds ratio) and diamonds the summary estimate from the pooled 
studies; 95% confidence intervals are indicated by horizontal bars and shown 
in parentheses. 
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Figure 6.3 Influence of CRM involvement on 5 year mortality in all patients  
with oesophageal carcinoma according to the CAP criteria. 
 
 
Figure 6.4 Influence of CRM involvement between 0.1 and 1mm on three  
year mortality in all patients with oesophageal carcinoma. 
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 Figure 6.5  Influence of CRM involvement between 0.1 and 1 mm on five year 
 mortality in all patients with oesophageal carcinoma. 
 
 
  
6.5 DISCUSSION 
The main findings from the 14 studies identified were that three and five year 
mortality in patients with CRM involvement according to both CAP and RCP 
criteria were significantly higher compared with patients without CRM 
involvement.  CRM involvement as defined by the CAP criteria differentiated a 
higher-risk group of patients than the RCP criteria as evidenced by the larger OR 
values in the three and five year mortality analysis of all patients. However, the 
group of patients overlooked by the CAP criteria did have a significantly poorer 
outcome compared to patients without CRM involvement. The RCP criteria 
therefore give important additional information compared with the CAP criteria. 
CRM involvement remained an important prognostic indicator despite being lower 
in patients who had undergone neoadjuvant chemoradiotherapy.   
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Fewer studies utilised the CAP criteria but analysis of studies utilising the RCP 
criteria resulted in heterogeneity limiting interpretation. The evidence for the RCP 
criteria was derived from reports regarding the surgical treatment of rectal cancer 
in which circumferential margins of less than 1mm were found to be important 
predictors of local recurrence and survival (Adam et al. 1994; Wibe et al. 2002). 
Arguably, application of these findings to the surgical treatment of oesophageal 
cancer is limited, as the oesophagus has no comparable anatomic boundaries 
such as the mesorectum, and is in close proximity to vital organs such as the 
heart, aorta and trachea. Oesophageal tumours therefore encounter a relatively 
small barrier to local invasion (Verhage et al. 2011). CRM involvement in 
oesophageal cancer is likely to reflect the presence of advanced disease rather 
than the performance of poor surgery and inadequate resection margin and CRM 
involvement according to the RCP criteria will consequently be higher (36.5 vs. 
15.3%).   
 
The presence of lymph node metastases appeared to negate the importance of 
CRM involvement with the odds ratio for three year mortality in patients with 
lymph node metastases straddling 1, indicating that CRM involvement was not 
associated with poorer outcomes. Conversely, the ORs for five year mortality 
were greater than 1, indicating that CRM involvement remained important. 
However, these outcomes should be interpreted with caution as only three 
studies which used the RCP criteria stratified for the presence of lymph node 
metastases (Griffiths et al. 2006; Sujendran et al. 2008; Scheepers et al. 2009). 
132 
 
The strengths of this study are the large sample size analysed, allowing the 
controversies surrounding the definition and prognostic significance of CRM 
involvement to be addressed. Only published studies were included as 
unpublished data from conference abstracts lack rigorous peer review. Two of the 
14 studies were ostensibly about other prognostic variables such as histological 
grade of tumour and the number of lymph node metastases (Thompson et al. 
2008; Mirnezami et al. 2010). The inclusion of such studies reduced concern 
about publication bias as the decision to publish was unrelated to CRM 
involvement and outcome. Moreover, in most analyses, heterogeneity was low, 
and there was no publication bias. Only high quality studies as assessed by the 
Newcastle-Ottawa score and studies with more than 100 patients were included 
in this analysis, thereby strengthening the conclusions. Most studies used similar 
histopathological specimen preparation and analysis, thus allowing comparison of 
CRM measurements.  
 
This study has limitations. Meta-analysis of retrospective cohort studies is 
regrettably sensitive to confounding. Many factors influence prognosis following 
surgery such as age, stage of disease, surgical technique and use of 
neoadjuvant chemotherapy or chemoradiotherapy. In attempts to reduce 
confounding, 12 studies adjusted for two or more of these variables during 
analysis. Subgroup analysis was limited, as not all studies reported separate 
outcomes according to stage of disease and treatment, and not all studies 
reported five year mortality. Three year mortality rates were therefore analysed, 
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as this allowed inclusion of four additional studies (Dexter et al. 2001; Sujendran 
et al. 2008; Saha et al. 2009; Salih et al. 2013).  
 
6.6 CONCLUSION 
CRM involvement is an important and significant predictor of poor prognosis. The 
issue of a threatened CRM forms an integral part of the wider argument relating 
to the most appropriate neoadjuvant therapy regimes for patients with operable 
yet locally advanced oesophageal cancer. Although CRM involvement as defined 
by the CAP criteria differentiates a higher-risk group of patients than the RCP 
criteria, this system overlooks the group of patients with poorer outcomes 
identified by the RCP system where there is tumour within 1 mm of the margin. 
Consensus regarding the most accurate and prognostically important definition of 
CRM involvement would be welcome; in the interim, arguably the exact nearest 
distance of the oesophageal tumour from the CRM should form part of routine 
pathology reporting in oesophageal cancer. 
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General discussion and prospect 
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GENERAL DISCUSSION AND PROSPECT 
The management of patients diagnosed with oesophagogastric cancer has 
evolved significantly over the past few decades. Despite contemporary 
multidisciplinary approach with improvements in staging and patient selection, 
outcomes remain poor when compared with other malignancies. This is largely 
the result of late presentation with advanced incurable disease, however radical 
surgery and toxic chemo-radiotherapy regimes are associated with significant 
morbidity.  
Further improvements can be achieved by increasing our understanding of the 
prognostic factors which may be gained from various staging modalities and the 
assessment of tumour histology which are used to guide management. This 
thesis examines key uncertainties and controversies in the staging and treatment 
of patients with oesophagogastric cancer. It follows the patient journey from pre-
operative staging after diagnosis, surgical treatment in the era of centralisation of 
specialist services, through to the examination of post-operative histological 
factors which influence prognosis. Specifically, this thesis addresses the 
combined role of PET/CT and EUS-defined tumour characteristics, the impact of 
centralisation on survival, the prognostic significance of HER2 expression and 
CRM involvement in patients with operable oesophageal cancer.  
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7.1 PET/CT AND EUS 
PET/CT has been integrated into contemporary radiological staging algorithms 
for patients diagnosed with oesophageal cancer with the confirmed benefit of 
upstaging and altering management in up to 25% of patients (Gillies et al. 2011; 
You et al. 2013). EUS is the principal modality for assessing local tumour 
characteristics including total length of disease and tumour volume which have 
been shown to be significant predictors of survival (Twine et al. 2010; Davies et 
al. 2012).  
Additional information such as the degree of tracer uptake by the tumour 
(SUVmax) and N stage can be obtained from PET/CT imaging. Although a high 
SUVmax was associated with poor survival only on univariate analysis, SUVmax 
correlated significantly and positively with EUS-defined tumour volume (Chapter 
2). This suggests that SUVmax may be used as a surrogate marker of tumour 
burden and could refine the prognostication of these patients. Moreover, along 
with EUS-defined tumour volume, PET/CT defined N stage was shown to be an 
independent predictor of poor prognosis. 
Future research would be directed towards assessing the relative accuracy of 
PET/CT in assessing peritumoural and distant lymph node metastasis when 
compared with histolopathological N stage. A comparison between PET/CT and 
EUS-defined length of tumour and tumour volume must be investigated to 
determine the most accurate modality as this additional information would guide 
surgical and neoadjuvant treatment. 
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7.2 CENTRALISATION OF UPPER GI CANCER SERVICES 
There has been a wealth of evidence supporting concentration and centralisation 
of oesophagogastric cancer surgery in large centres resulting in significant 
improvements in both short-term surgical outcomes and long-term survival 
(Anderson et al. 2011; Brusselaers et al. 2014). Despite the recommendations 
from the NHS Improving Outcomes Guidance which advocate centralisation of 
upper gastrointestinal services in units performing a minimum of 15 resections 
per year, progress has been slow and sporadic. Of the centres which have 
centralised, only a few have reported short-term outcomes after reconfiguration of 
services.  The only report from Wales has shown that centralisation resulted in 
lower morbidity, mortality and length of hospital stay in patients undergoing 
surgery (Chapter 3). Moreover, one year survival increased in all patients 
diagnosed with oesophagogastric cancer. These positive results will lend support 
to reconfiguration of services in other areas and specialties.  
The reasons for the witnessed improvements are multi-factorial; more frequent 
MDT meetings, improved staging and patient selection, increased use of 
palliative chemotherapy and improved peri-operative care. The South-East Wales 
Upper GI Cancer Network serves a population of 1.4 million, most of whom 
reside in areas of significant socio-economic deprivation resulting in diagnostic 
delays which may negatively influence outcomes. Further research investigating 
the effects of deprivation and diagnostic delays on outcomes will guide health 
policy makers to prioritise funding into preventing these delays.    
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In tandem with centralisation, the enhanced recovery after surgery programme 
was established after unequivocal evidence supporting its benefits in colorectal 
surgery. Future research must be directed towards establishing its safety in 
oesophagogastric surgery and identifying the significance of individual 
components of the programme. This includes preoperative optimisation of 
patients’ nutritional status as malnutrition is associated with poor outcomes. 
Patients with oesophagogastric cancer are especially likely to suffer from 
substantial weight loss. Objective assessments of sarcopaenia with CT-
measured psoas muscle density and body composition with bioelectrical 
impedance analysis would further contribute to the understanding of how these 
physiological factors can be optimised to improve outcomes. 
An important aspect of centralisation of cancer services that has been neglected 
is its economic impact (Ke et al. 2012). It is still not known if centralisation 
increases or decreases the overall costs to the NHS and if it is cost-effective in 
terms of quality-adjusted life years. Centralisation also leads to increased costs of 
accessing healthcare by patients and their carers and the overall impact on them 
will need to be quantified. There has been a trend towards centralisation of 
cancer services despite the lack of evidence that it will lead to cost-effective care. 
Therefore, there is a strong need for good quality studies aimed at determining 
which aspects of centralisation which would lead to efficient health care, thus 
informing policy decision makers in the reorganisation of cancer services. 
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7.3 HER2 OVEREXPRESSION AND AMPLIFICATION 
Over the last decade, drugs targeting different growth factors and their receptors 
have been championed in the treatment of various cancers. The role and 
prognostic significance of these various growth factors in oesophagogastric 
cancer remain uncertain. Targeted therapy towards the HER2 receptor 
(trastuzumab) is currently used with palliative intent in patients with advanced 
gastric cancer with evidence of HER2 overexpression or amplification. The 
relationship between HER2 overexpression in oesophageal cancer is 
controversial. Reports vary in the method of identifying HER2 overexpression and 
the heterogeneity observed in oesophagogastric tissue samples add to the 
uncertainties. The findings reported in the meta-analysis of 14 studies confirm 
that HER2 overexpression and gene amplification was a significant predictor of 
poor prognosis in patients with operable oesophageal cancer (Chapter 4). 
Although these findings were not reproduced in our unit due to the small sample 
size, the results from Chapter 5 showed that endoscopic biopsy had a high 
specificity and negative predictive value in determining HER2 status. 
Future research must be directed towards the role of anti-HER2 therapy in the 
neoadjuvant setting prior to oesophagectomy and in the palliative setting in 
patients with advanced oesophageal cancer. Although recruiting sufficient 
number of patients for these trials would be difficult in individual units, a well-
designed, multi-national collaborative could overcome these recruitment 
challenges. 
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7.4 CRM INVOLVEMENT 
The prognostic role and definition of CRM involvement in oesophageal cancer 
are widely debated issues and currently, no formal consensus exists. The 
findings reported in Chapter 6 are arguably the most significant of this thesis. The 
meta-analysis of 14 studies of over 2400 patients with operable oesophageal 
cancer confirms the significance of CRM involvement as a predictor of poor 
prognosis. Moreover, the definition of CRM involvement according to the CAP 
criteria differentiates a higher-risk group than the RCP criteria, but overlooks a 
patient group with similar poor outcomes. The RCP criteria therefore give 
important additional information when compared with the CAP criteria. Whilst a 
consensus is being reached, the exact nearest distance of the tumour from the 
CRM should be reported in oesophageal cancer. 
The issue of an involved CRM forms an integral part of the much wider argument 
regarding the optimum neoadjuvant therapy regimes for patients with operable 
yet locally advanced oesophageal cancer. The rates of CRM involvement were 
lower in patients who had undergone neoadjuvant chemoradiotherapy. Future 
research should therefore be targeted towards identifying the role of neoadjuvant 
chemoradiotherapy in patients with T3 tumours who have a high risk of CRM 
involvement. The results of the NeoSCOPE trial, a multi-centred trial based in 
Cardiff of two pre-operative chemoradiotherapy regimes are greatly anticipated 
(Gwynne et al. 2013). 
Definitive chemoradiotherapy has been shown to be an effective alternative to 
surgery in patients with oesophageal cancer in various case series. However, no 
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randomised controlled trial (RCT) has been conducted to compare these 
treatment modalities. Propensity score analysis is an alternative to RCTs in 
situations when interventions cannot be allocated randomly as it adjusts for 
potential confounders such as baseline demographics or interventions in 
observational data (Austin 2011). Such analyses can be used to determine the 
outcomes of dCRT in patients with oesophageal cancer from large observational 
studies. 
 
7.5 CONCLUSION 
The diagnosis of oesophagogastric cancer is still considered to be a sentence of 
death by many clinicians. However, significant improvements in staging, 
perioperative care, surgical and oncological treatment have been achieved and 
continue to challenge this view. Further research should strive to increase earlier 
diagnosis and accurate stage directed multidisciplinary treatment will remain to 
be the foundation of the management of these patients. The hypothesis and 
results generated in this thesis should be built upon to further improve treatment 
algorithms and outcome for patients with oesophagogastric cancer. 
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